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Abstract 
High-throughput proteomics approaches have been successfully employed in the inclusive and unbiased 
characterization of cellular proteome. In this thesis, we are aiming to comprehensively compare changes in 
proteome expression in mammalian cell lines under two different conditions. The first is an analysis of 
mAb producing CHO cells with a focus on comparing the productivity of inducible cells, and the second 
investigates human colorectal cancer cells with a focus on chemo-resistant cells. To this end, the 
quantitative proteomics technique iTRAQ was performed on the samples. 
The production of monoclonal antibodies as therapeutic medicines has gained increasing attention and 
applications in the last decades. Improving production levels is an important issue that can economically 
impact the industry. Chinese hamster ovary (CHO) cells are the most commonly used mammalian cell lines 
for the production of therapeutic mAbs and have been genetically modified for this purpose. Monitoring 
the effects of genetic modification systems on the cells is very important to maintain the quality and 
consistency of the cellular products. The possible changes or stresses forced on the cells after these 
modifications can be observed by analyzing the cells’ proteome and can enable the development of 
optimized expression systems. Also, the biological characteristics of high-producing CHO cells could be 
obtained by proteomic comparison of these cells. 
We quantified the expression levels of 1,616 unique proteins from an iTRAQ MS analysis and identified 
81 proteins with p-values lower than 0.05 where the highest fold-change belong to the mAb sequence. 
Overall, proteins did not show any large changes based on the fold-change and it is likely that the induction 
system with cumate gene switch did not cause large metabolic changes or stress responses in the CHO cells. 
With these results we can suggest that the system has generated a stable cell line with a higher capacity for 
mAb production without inducing any major stress responses in the cells, and the cell line could have the 
potential for high mAb production using a stronger promoter system. 
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The second topic of interest in this thesis is therapy resistance colorectal cancer, which is either caused 
by a selection or induction of drug resistance in a subset of colorectal cancer cells. Drug resistance is the 
first reason for treatment failure or metastasis, therefore understanding the biological features of resistant 
cells can be helpful. To this end, the cancer cell line, HT-29, and a SN-38 drug-resistant HT-29 cell line 
were explored by iTRAQ quantitative proteomics analysis. SN-38 is the active metabolite of the 
chemotherapy drug, irinotecan, a common mediation for treating colon cancer. 
The expression levels of 1,665 proteins were quantified and 21 proteins had significant changes with 
more than 1 log-fold-change. PAGE4 is the most up-regulated protein in the resistant HT-29 cells; it shows 
to have a role in cell viability and survival. Among the down-regulated proteins, cytokeratin (KRT20) had 
a significant low expression in resistant HT-29 cells that can show the change in cell migration because it 
is known for circulating CRC cells. Biosynthesis of antibiotics is identified as the most enriched KEGG 
pathway within the up-regulated genes; also, ribosome pathway is observed as the most enriched pathway 
among the down-regulated gene list. Overall, a large number of the differentially regulated genes were 
known in the stem cancer cells, EMT processes and metastasis. The main functions among the differentially 
regulated proteins is related to cell adhesion and migration, cell proliferation, and the ribosome. 
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Chapter 1 
Introduction 
1.1 Proteomics study of CHO cells 
1.1.1 An introduction to monoclonal antibodies 
At the beginning of 20th century the Nobel laureate Paul Ehrlich introduced the concept of antibodies; he 
coined the term “magic bullet” to describe ‘drugs that go straight to their intended cell-structural targets’ 
[1]. Ehrlich’s works inspired many scientists, and has led to discovery of successful treatments including 
novel chemotherapeutics. In 1975, Köhler and Milstein made the first hybridoma cell for producing 
monoclonal antibodies (mAb) by fusion of “a mouse myeloma and mouse spleen cells from an immunized 
donor” [2]. This discovery brought them  the Nobel prize for Physiology or Medicine in 1984 [3]. Early 
applications of mAbs were primarily for diagnostic purposes. Therapeutic applications of mAbs were not 
evident until 1986, when the first mAb product, Orthoclone OKT3 (muromonab-CD3), was approved for 
use in treating and preventing graft versus host disease in transplant patients [4]. 
The approval of recombinant proteins and mAbs as treatments for different autoimmune diseases and 
cancers has brought more attention to the production technology. In 2014, six mAbs were listed in the top 
10 best-selling drugs, and overall sale of these mAb products has reached 60 billion USD per year [5]. 
Currently, around fifty monoclonal antibodies are approved and available on the market, and it is anticipated 
that around seventy monoclonal antibodies will be on the market by 2020 [6]. In the recent years, worldwide 
sales of all monoclonal antibody products have had a higher growth compared to other recombinant 
therapeutic proteins. For example, from 2008 to 2013 mAbs market had an increase of about 90% (from 39 
billion dollars to about 75 billion dollars), while other recombinant protein therapeutics had only 26% in 
that time period [6]. Most of monoclonal antibodies in the market are produced using mammalian cell lines. 
Chinese hamster ovary cells (CHO), baby hamster kidney (BHK), murine myeloma derived (NS0), human 
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embryonic kidney (HEK-293), and the human retina-derived PerC6 are the main mammalian host cell lines 
used in the industry. Among these cell lines, CHO cells are the host cell line for nearly 70% of recombinant 
protein therapeutics [7]. 
Subsequently, the competition in the field of biopharmaceuticals has increased. This is partly because 
some of the patents for the recombinant protein therapeutics including mAbs have expired or are due to 
expire soon, therefore other manufacturers in countries like India and China have entered the market to 
produce the generic version of these biologic drugs, also called biosimilars. From other aspects, the access 
to bioinformatics tools has increased and the release of the first draft of genome sequence of CHO cells in 
2011 has facilitated the study of these cells in depth [8]. Gaining more information about the cells growth 
and protein production mechanisms could lead to developing and improving the methods of optimizing 
production of mAbs. 
1.1.2 Host cell lines 
A first step in producing recombinant proteins including mAbs is to find the right host cells that could be 
used to express the protein of interest. As a rule of thumb, smaller proteins (smaller than 30 KDa) that do 
not have complicated post-translational modifications could be produced in model prokaryotes such as 
Escherichia coli. These bacterial systems are cheaper as the bacteria grows faster and the medium used for 
growing the bacteria is much cheaper to the ones used for growing eukaryotic cells, especially for 
mammalian cells. Normally larger proteins (greater than approximately 100 kDa) cannot be expressed in 
bacterial systems. Eukaryotic cells such as mammalian cells, fungi or baculovirus systems could be used as 
a host for expressing these large proteins. In addition to the size of the protein other important factors such 
as required post-translational modification for the protein of interest also should be considered in choosing 
the right expression system. For example glycosylation, which is an important post-translational 
modification in mAbs, cannot be done by prokaryotic systems such as E. coli. Also, disulfide-rich proteins 
cannot be expressed properly in E. coli. Sometimes even proteins of interest that are normally expressed in 
eukaryotes could be toxic to prokaryotic cells and therefore cannot be produced by these cells [9]. Other 
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expression systems for production of recombinant proteins also exist, such as using plants and transgenic 
animals, such as expression of mAbs in tobacco plant and production of recombinant proteins in milk, egg 
white, blood or urine of transgenic animals like mice, pigs, or rabbits, but they have not gained as much as 
popularity as mammalian cell expression systems so far [9, 10]. 
An antibody is constructed of two heavy chains and two light chains that are connected through hydrogen 
bonding, van der Waals interactions, and disulfide bonds. A general overview of the structure is shown in 
figure 1.1. Light chains are comprised of a variable domain and a constant domain, while heavy chains are 
have a variable domain and three constant domains. The antigen binding region of a mAb (Fab region) 
contains the heavy chain and light chain variable domains; this fragment determines the specificity of the 
antibody. The fragment crystallizable (Fc region) is made up of constant heavy chain domains that are 
glycosylated, and is responsible for effector functions and the extended half-life of the molecule in the body 
(Figure 1.1) [11]. 
Monoclonal antibodies are complex glycoproteins; after their expression by the cell they go through 
important post-translational modification called glycosylation. During this modification, glycans that are 
certain carbohydrate moieties, bind to the proteins to build the mAb’s structure. Glycosylation plays an 
important role in the structure and the reaction of the body to the mAb. The glycosylation pattern could 
highly affect the protein stability, biological activity e.g. antibody-dependent cellular cytotoxicity (ADCC), 
and also it affects the pharmacokinetics of the monoclonal antibodies [12]. 
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Figure 1.1: A generalized structure of a glycosylated mAb. 
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The correct glycosylation pattern is critical for having functional glycoforms that do not have 
immunogenic effects and do not clear quickly from the body [13]. Factors such as the enzymatic pathways 
of the host cell and the culture conditions impact the glycosylation patterns of secreted protein of interest 
[14]. To this end, the host cells for mAb production that determine the characteristics of product are the 
important key to the biopharmaceutical products. For example, insect cells normally are not able to produce 
these glycosylation patterns that are similar to the patterns in human antibodies. Among the different 
eukaryotic cells mammalian cells could express proteins with more similarity to the ones expressed in 
human cells with proper folding and glycosylation forms without the need for renaturing the product. 
Among the mammalian cells Chinese hamster ovary (CHO) cells have become the workhorse for producing 
complex therapeutic proteins such as mAbs [9]. In the next section, I will review these cells and the process 
of production. 
1.1.3 Chinese Hamster Ovary Cells 
In 1919, Chinese hamsters were first used as a substitute for mice in pneumococcal typing. Later on, low 
number of chromosomes in Chinese hamsters made them a model for radiation cytogenetics and for cell 
culture studies [15]. In the late twentieth century, female Chinese hamsters became vital tools for the 
development of molecular biology. The mammalian genetics studies had progressive improvements by 
research on the donated ovary cells, and they continued to be an essential part of biotechnological science 
and industry [13]. The first CHO cell line was developed in the late 1950s by Dr. Theodore Puck at the 
University of Colorado [16]. Since then these cells were used in in-vitro studies and many different 
modifications on them was implemented for different application purposes from lab-studies to being a cell 
factory for producing biologics [15]. The first protein therapeutic produced by CHO cells as the host was 
human tissue plasminogen activator (tPA, Activase) (Genentech, San Francisco, CA, USA). This product 
was approved for human use at 1986 by the FDA. In this section, I summarize the process of making protein 
therapeutics in CHO cells. Normally for the production of every recombinant therapeutic protein three 
overall steps should be undertaken, as described below. 
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As a first step, the gene which is responsible for production of the protein of interest should be expressed 
by the cells. To introduce the gene of interest, expression vectors are designed that will insert the gene into 
the host cells and ensure that a suitable transcription factor system is in place. After the gene of interest is 
cloned into the optimized expression vector, the host cells are transfected for integration of the gene in the 
host genome. Finally, as not all of these clones will have the desired characteristics, selecting the best clones 
is the next step by which we can optimize the expression levels of the protein [13]. This is the up-stream 
process, in which an engineered cell line for producing the protein of interest is created and should be 
preserved in a cell bank for further use [16].  
At the second step of production, the CHO cells prepared during the upstream process are cultured and 
extended through culture flasks, small bioreactors, and lastly to a large bioreactor setup that has the capacity 
to support producing enough of the target protein. Production CHO cell lines are mostly adapted to grow 
in suspended cell culture so that it is easier to grow them in stirred tank bioreactors. The protein of interest 
is typically released in the culture medium. This step is usually called fermentation or mid-stream; 
sometimes the first two steps together are called the up-stream process [16]. 
The down-stream or purification step includes the use of separation techniques such as filtration and 
different types of chromatography techniques. In this part of the process the desired protein is purified and 
any impurities such as remnants of bacterial and viral contamination are removed, de-activated or excluded 
from the product. The result of this step is normally called Active Pharmaceutical Ingredient (API) that can 
be stored for the formulation and finishing step in which additives such as sugars (sorbitol) are added to the 
API to gain the proper specification for use as an effective, safe drug in humans [17]. 
In manufacturing mAbs for therapeutics, the CHO cells and their productivity acquire a special attention. 
These cell lines are considered suitable for scale up in bioreactors because the well-developed selection and 
gene amplification systems allow us to produce stable mAb-producing clones. Also by producing glycan 
structures similar to those of human mAbs, CHO cells are one of the most suitable and preferred host cells 
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for mAb production [18]. To ascertain the consistency between produced mAbs, accurate screenings of 
production cell lines have to be performed. These screening steps are costly and time consuming which 
lead to an expensive final products and delay in introducing the products to the market. Major advances for 
increasing the CHO cells’ productivity have been achieved in operational processes, such as culture media 
optimization and better feeding strategies [19]. However, further studies are required to improve our 
understanding of the intrinsic features of these cells. That being said, bioinformatics studies of the cells can 
help us to understand the specific characteristics that change the productivity of cells. 
1.1.4 Development of cell lines with high productivity 
In generating CHO cell line that can produce a specific protein, typically clonal selection is performed after 
transfection of the gene of interest. Some of the most common modifications in developing CHO cell line 
is to increase the performance in selection through amplification systems using dihydrofolate reductase 
(DHFR) and glutamine synthetase (GS) genes [20, 21]. The DHFR system is provides methotrexate (MTX) 
resistance and the GS system confers methionine sulfoxamine (MSX) resistance. 
Methotrexate binds to DHFR and stops it from catalyzing folate to tetrahydrofolate. Tetrahydrofolate is 
a necessary precursor in the synthesis of purines, pyrimidines and glycine [21]. Therefore, if there are low 
levels of DHFR cells are deprived of nucleosides and die. The CHO cells will be transformed with 
recombinant DNA including the gene of interest and the DHFR gene. The cells are cultured in increasing 
levels of MTX for gene amplification, and only CHO cells with high expression of the DHFR gene can 
grow in this condition. In the GS system, the product of GS enzymatic reaction with glutamate and ammonia 
is glutamine. Methionine sulfoxamine (MSX) prevents the glutamine production by binding to the GS 
enzyme. Similar to the DHFR/MTX system, gene amplification happens with subjecting to increasing 
concentrations of MSX. 
 
  
8 
1.1.5 Gene expression systems and vectors 
Normally, in the development of recombinant CHO cell lines the random integration of a vector containing 
the gene of interest (GOI) occurs and then in a selection process, cells that carry the GOI will be selected 
[22]. This random integration of the GOI usually causes the cells to have non-homogenous phenotypes that 
some of these phenotypes might be unwanted [22]. Usually an extensive cell screening should be taken to 
find the clone with the desired specification for the protein production. For example in a study 120,000 
CHO clones were screened for selecting the healthy ones [23]. To overcome this issue, site specific 
integration of transgene targeting could be a useful strategy [7, 22]. Genes encoding proteins such as zinc-
finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly 
interspaced short palindromic repeats (CRISPR)-associated (Cas) RNA guided nucleases are common 
examples of tools for targeted insertion/deletion (indel) mutations or an accurate sequence  alterations in a 
cell [22]. 
Vectors are DNA molecules that can replicate and we use them for transferring DNA fragments to 
cells. Vectors derived from mammalian viruses are the most commonly used vectors for expressing 
heterologous genes in mammalian cells, such as, simian viruses 40 (SV40), polyoma virus, and herpes 
virus [20]. SV40 or a promoter from cytomegalovirus (CMV) is the most famous vector for transient 
gene expression with a strong viral promoter [24]. Adenovirus is medium sized (90–100  nm), non-
enveloped virus holding a double stranded DNA genome. One advantage of using this virus as a vector 
is that this virus can be propagated in suspension cell cultures [24]. Vaccinia vectors are other common 
viral vectors for transferring genes to mammalian cells. Cells infected with the vaccinia virus produces 
large amount of virus particles per cell (up to 5000), which makes the vaccinia system being able to 
support high levels of recombinant protein expression. Companies such as Immuno AG have used the 
vaccinia system for large scale (e.g. ≥ 1000 L reactor) protein production. 
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1.1.5.1 Lentiviral vectors 
A time consuming and costly procedure in the development of CHO cell lines is the cloning and selection 
of the best-performing clones. One of the approaches for dealing with this issue is transient transfection of 
vectors into CHO cells. This is a rapid method that has been used for producing recombinant proteins in 
research or preclinical studies. A group of researchers at the Biotechnology Research Institute of the 
National Research Council of Canada in Montreal have been working on a new approach based on infection 
of cells by lentiviral vectors (LVs). 
LVs are a type of retroviruses that are more complex and able to infect dividing and non-dividing cells. 
They incorporate their genome into the chromosome of the cells for stable transgene expression [25]. In 
2007, Gaillet et al. developed a new approach for improving the transient expression of proteins in CHO 
cells. The method is based on the cell infection by viral vectors and the cell line used in this study was made 
by the system that was developed from this method. 
A lentiviral vector includes the gene of interest and required regulatory sequences, also, plasmids that 
encode enzymes and proteins for making virions are often used for production of LVs [22]. However, the 
method of co-transfection is costly and difficult to scale up, and production of a large quantity of LVs is 
easier with packaging cell lines or vector producing cell lines (VPCLs) [26]. Packaging cell lines can stably 
express all proteins for making virions [25]. In 2008, Broussau et al. created a new inducible packaging cell 
line that efficiently produces high quantities of the lentiviral vector. As assessed using green fluorescent 
protein (GFP), the production was able to reach titers greater than 3.0*107TU/ml, though this will vary 
based on the size and the sequence of the transgene. 
1.1.6 Development of Inducible Cells by Transduction System 
An important controlling factor of recombinant protein production is transcription promoters and enhancers. 
For example, the human cytomegalovirus (CMV) is a common promoter used for expression of human 
recombinant protein and CMV5 is a version of CMV, which carries an enhancer sequence and some other 
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features such as splicing sites present in the Ad5 MLP [18]. Furthermore, this promoter has the ability for 
efficient mRNA translation which results in a much higher protein expression as compared to a standard 
CMV promoter [18]. CMV5 is the optimized version of CMV promoter that is usually used in CHO or 
other mammalian cell expression systems. The new inducible expression system demonstrated that CHO 
cells with CR5 promoter are stronger than CMV5 in either of the vectors, adenovirals or lentivirals [26]. 
In the cumate gene-switch system, the cumate transactivator (cTA) or the reverse cTA (rcTA) binds to 
the CR5 promoter and initiates transcription (Figure 1.2). Addition of cumate, the small non-toxic molecule, 
prevents or induces binding of cTA or rcTA to the CR5 promoter, respectively [27]. The capacity of this 
new system has been evaluated by constructing several LVs carrying different cDNAs. 
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Figure 1.2: The cumate gene switch mechanism. In the reverse activator configuration, with 
the presence of cumate and binding with reverse cumate transactivator (rcTA), the transcription 
will be initialized from the CR5 promoter. 
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1.1.7 Application of OMICs tools to MAb production 
OMIC tools are useful techniques for understanding the mechanism of cell growth and protein production 
at the different level of genome, and proteome, metabolome. Since the introduction of these methods, there 
have been different studies exploring CHO cell features, however the CHO genome sequence was not 
available until 2011. Thus researchers had to rely on the available data from similar species such as mouse 
and rat [28]. In 2011, the genomic sequence of CHO-K1 cells was published, facilitating high-throughput 
studies on CHO cell lines [8]. In the genomic and transcriptomic study performed by this group, 24,383 
predicted genes and 11,099 transcripts were identified in CHO-K1 cell line [29]. Several studies afterwards 
improved on the identified CHO protein lists, and the collection of this information assists interpretation 
and brings more confidence in analysis of proteomic results from CHO cells [29, 30]. 
In a proteomics study by Orellana and colleagues, CHO cells that were producing higher amount of mAb 
have shown to have higher content of the antioxidant glutathione [31]. Glutathione (GSH) potentially has 
several benefits in the process of producing high amounts of mAb in a cell. GSH works as a storage 
component for cysteine, which may be used during protein translation and modification. It can also reduce 
cysteine disulfides and as the result providing more cysteine available for protein synthesis. In 
hyperoxidizing environments, correction of protein disulfide bond formation is another beneficial role of 
GSH [31]. 
In a metabolome analysis study, Chong et al. [32] explored differences in biological pathways of CHO 
cell lines producing different levels of mAb. They discovered that the amount of interacellular NAD 
(nicotinamide adenine dinucleotide) and FAD (flavin adenine dinucleotide) were higher in a high producer 
cell line compared to a low producer cell line. The high producer cells need more energy for protein 
synthesis. Mitochondria provides energy in the cells by the oxidation of sugars, fatty acids, and amino acids. 
NAD and FAD (reduced to NADH and FADH2) carry electrons though the electron transport chain. 
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The above examples of OMICs studies show that bioinformatics approaches could be instrumental in our 
understanding of the biologic systems such cell lines use in the production of therapeutic recombinant 
proteins at high levels. The findings demonstrate that using OMICs approaches we would be able to identify 
factors leading to increased MAb production in CHO cells. 
1.2 Proteomics of colorectal cancer HT-29 cells 
1.2.1 Introduction to Human Colorectal Cancer 
Human colorectal cancer (CRC) is the third most common cancer worldwide. According to the American 
cancer society report 2017, it is the second leading cause of cancer death in men and the third in women. 
During the past decade, the mortality rate of CRC had about 3% decrease each year (American cancer 
society, CRC facts and figures, 2017). While there have been major developments in cancer therapies and 
increases in taking screening tests, CRC is still one of the deadliest cancers in the world. One of the 
important issues in treating patients with metastatic tumors is that cancer cells can become resistant over 
time to several options for treatment [33]. 
Tumor excision by surgery is the first option for treatment, but relapse occurs in almost half of the 
patients after removing localized tumors [33]. The first set of standard chemotherapy treatments involves 
folinic acid, 5-fluorouracil, and irinotecan or oxaliplatin which both have a broad equivalent effect [34]. In 
addition, some combinations of these therapeutic agents have shown better overall response and survival 
rates in patients [34]. In this thesis, the focus is on a CRC cell line that became resistant to treatment by 
SN-38, the active metabolite of irinotecan. 
In the early 1970s, camptothecins (CPT) failed in first phase of clinical trials because of excessive 
toxicity. However, the interest in camptothecin as an antitumor drug renewed after identification of the 
molecular mechanism of this action [35]. Camptothecins inhibit DNA synthesis by inducing fragmentation 
of chromosomal DNA, which is partially reversible. Inhibition of RNA synthesis is also reversible by drug 
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removal [36]. Potential anticancer agents, topotecan and irinotecan are derived from CPTs and later 
approved by FDA for treating ovarian and lung cancer, and colorectal cancer respectively [36]. 
In the 1990s, camptothecin analogs became effective treatments for several malignant cancers, especially 
colorectal cancer, for which only a few treatment options were available at the time [37]. Irinotecan is a 
camptothecin derivative (CPT-11) that is biologically inactive. This compound is catalyzed in a 
carboxylesterase-mediated hydrolysis reaction, which converts it to its active metabolite, SN-38 [38]. In 
humans, carboxylesterases are present in liver, intestine, and plasma, and they have an important role in 
drug metabolism [38]. 
To understand the mechanism of treatment by the inhibitors the role of TOP1 is briefly described. This 
enzyme cleaves DNA to make a single strand break and stays covalently bound to the strand [39]. This 
action allows DNA to rotate and relax and then TOP1 ligates the DNA strand and releases the relaxed DNA 
[39]. Irinotecan or CPT-11 interrupts DNA synthesis by preventing the activity of topoisomerase I and 
makes protein-linked DNA breaks at replication forks [39]. This single strand breakage leads to a double 
strand break at replication forks, subsequently activating DNA repair systems. When a cell fails to repair 
the DNA due to inefficient repair pathways, the cell goes through cell-cycle arrest and apoptosis [35, 39]. 
Therefore, the effect of TOP1 inhibitors on cancer cells depends on levels and activity of TOP1 enzyme in 
cells and efficiency of DNA repair process [36]. 
Camptothecin (CPT) derivatives target the nuclear enzyme DNA topoisomerase I (TOP1). This 
mechanism has been successfully utilized in cancer treatment. During the S phase of the cell cycle the 
replication fork will make permanent breaks and cause S phase cell cycle arrest [35]. This cytotoxic process 
happens in two steps – first, the drug will cause accumulation of cleavage complexes containing reversible 
DNA single strand breaks, then these complexes will be turned into permanent DNA single and double 
strand breaks [35]. 
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That being said, the effectiveness of this treatment may be altered by other elements that are involved. 
There is the potential that tumors can become resistant to the therapeutic agents [40]. Drug resistance is 
known to be the most common reason in failed cancer therapies, and more than 90% of metastatic colorectal 
cancer patients have shown resistance to chemotherapy drugs [40]. 
1.2.2 Therapeutics for colorectal cancer 
One of the major advances in treating colorectal cancer patients is irinotecan, along with fluorouracil (FU), 
used as a single drug or a combination with other drugs it was approved in the 1990s. Irinotecan was 
valuable for treating patients and has become a standard of treatment [37]. The pharmacokinetics of this 
class of drugs has been complicated to understand. Like drugs that undergo hepatic disposition, the 
excretion of SN-38 is happening by glucuronidation; also, SN-38 can be oxidized by the cytochrome P450 
family [41]. Glucuronide formation (SN-38G) can also be reversed by bacteria in the intestine. A small 
amount of the irinotecan will be converted to SN-38 in the patient’s body and the excess of drug will be 
metabolized, excreted by liver or renal transport [41]. The effectiveness of irinotecan may also be 
influenced by expression levels of other proteins such as transporters and DNA repair proteins, discussed 
below.   
In vitro studies have shown that drug efflux can change via ATP-binding cassette (ABC) transporter 
proteins, which are involved in passage of drugs through cells and tissues [42]. The expression level of 
proteins such as P-glycoprotein (P-gp) and multi-drug resistance protein (MRP) are correlated with 
chemotherapy resistance in cancer cells. Research on these proteins has shown P-gp has very high 
expression levels in drug-resistant cell lines [43, 44].  
TDP1, tyrosyl-DNA phosphodi-esterase 1, is a DNA repair enzyme that in various situations can remove 
covalent adducts from DNA [45]. Meisenberg et al. (2015) studied the role of TDP1 and TOP1 in cellular 
response to TOP1-inhibitor treatments. TDP1 removes the TOP1 peptide from TOP1–DNA breaks and this 
happens at the beginning of the repair process, so it is critical in starting the DNA repair. In addition, this 
  
16 
enzyme has a role in the resolution of DNA damage through TOP1 [46, 47]. Therefore, changes in the 
TDP1’s activity can improve efficacy of treatments by TOP1 targeting chemotherapies [48]. Meisenberg et 
al. showed that polypeptides of both TOP1 and TDP1 had various expression levels in CRC cell lines and 
clinical tumor samples [49]. Depletion of TDP1 has outcomes that make TOP1 inhibitors a potential 
treatment option in colorectal cancer [49]. In the case of TDP1 depletion, DNA breakage increases and 
irinotecan sensitivity, depending TOP1 levels, can significantly increase [49]. 
New strategies have been developed to overcome some of the known causes of resistance, such as P-gp 
inhibitors [43]. Elacridar, tariquidar, and zosuquidar are some of these products that effectively enhance 
chemotherapy sensitivity in clinical studies [40]. The intrinsic mechanism underlying the drug resistant 
cells still needs to be explored from different perspectives. The knowledge on the cellular mechanism of 
resistance in cancer cells could assist physicians to decide whether TOP1 inhibitors or a combination with 
other inhibitors might be beneficial in treating patients based on the features of their tumors. Incorporation 
of tumor-specific features into treatment plans could have a substantial effect in increasing survival rate. 
1.2.3 HT-29 cell line background 
Colorectal cancer tumors can be categorized into two groups based on the type of genomic instability. The 
majority of CRC patients’ tumors have chromosome instability (CIN), where chromosomes might be 
duplicated or deleted completely or partially, so number or structure of chromosomes is abnormal. In some 
cases, tumors have microsatellite instability (MSI) at the nucleotide level, which is caused by impaired 
DNA mismatch repair [50]. The HT-29 cell line with chromosomal instability and HCT-116 cell line with 
microsatellite instability are the most common cell lines to be used in research studies. 
Researchers in Dr. Blay’s lab at the University of Waterloo have generated a derivative of HT-29 cell 
line by treating with the irinotecan active metabolite, SN-38, that is SN-38 resistant and studied dynamics 
of the cell cycle as they become resistant to the drug [51].  
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1.2.4 Classical resistance mechanisms 
A drugs’ efficacy depends on the drugs accumulation in target tissues, which could be limited by how much 
it enters or leaves cells. The absorption and accumulation of substances with potential toxicity is limited by 
active efflux mechanisms in the plasma membrane. Drug resistance in cancer cells could occur through 
these efflux mechanisms, by up-regulation of proteins, such as P-glygoprotein (P-gp, MDR1) and multi-
drug resistance protein, MRP2. These efflux pump proteins transport compounds (hydrophillic or charged) 
from cell’s cytosol to extracellular matrix or into lysosomes. By removing drug substances, efflux proteins 
can increase resistance to drugs and therefore reduce efficacy. This mechanism of drug resistance has been 
shown in vitro by analysis of resistant cell lines and clinically in patients at the time of failed treatments 
and relapse. For example, the RNA levels of BCRP were significantly over-expressed in leukemia patients 
between the diagnosis time and the relapse time at a refractory state in comparison to the diagnosis time 
[52]. 
Expression of drug efflux pumps are associated with irinotecan resistance, ABC transporter superfamily 
proteins ABCG2/BCRP and ABCB1/p-glycoprotein (Figure 1.3) [53, 54]. CRC cells resistant to SN-38 had 
significantly over-expressed ABCG2 protein [55]. Physiological characteristics of cells, such as growth and 
dynamics of cell cycle, have also shown changes in SN-38-resistant CRC cells. SN-38 resistant cells 
showed a slower growth, the S phase fraction of cell cycle was reduced, while the G2/M phase showed an 
increase [56]. One of the results of a longer G2 phase is the accumulation of cyclin B1 in the cytoplasm 
during this phase. There is also confirmation of this result in vivo, with observed slower growth and reduced 
DNA synthesis. 
In addition, genetic polymorphism in transporters can change the drugs metabolism and dis-positioning, 
therefore individuals can show variable pharmacokinetics [39]. These chemo-refractory tumors are active 
in adapting and advance with alternative drug-resistance programs; as a result, ABC transporter inhibitors 
have typically not had promising results [57].  
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Overall, changes in the efflux and influx of the molecules out of and into the cells are the most important 
factors in the drug resistance process. In addition, in the irinotecan treatment activation of DNA repair 
mechanism and drug detoxifying proteins, and disruption in signaling pathways for apoptosis (Figure 1.4). 
Here, we are interested to examine the proteome of our SN-38-resistant colorectal cancer cells to identify 
the components involved in the resistance mechanism. 
 
 
Figure 1.3: An overview of the pathway of irinotecan disposition in and out of cells [58]. 
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Figure 1.4: Some of the cellular factors that are involved in drug resistance mechanisms. 
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1.2.5 The role of fibronectin and integrins 
Fibronectin was discovered in 1973, as a surface antigen protein that is produced by fibroblasts in chicken 
[59]. In another publication, it was identified as a large extracellular protein in hamster and human fibroblast 
cells by experiments using radio-labeling of surface proteins [59, 60]. Later, the nature of these extracellular 
proteins and actin microfilaments was understood to be functionally linked together. Now we know that the 
integrins are a family of cell surface receptors that make the link between extracellular proteins and 
cytoskeleton [60, 61]. 
There are 18 integrin α subunits known in humans. The integrin subunits, α and β, form heterodimers 
and make receptors with unique structures that have particular functions. By attaching cells to the ECM 
substrates, these proteins are providing information about the extracellular environment to the cell as well 
as returning signaling information [62]. This connection can regulate intracellular signaling pathways and 
behavior of cells. Also, with these cell interactions information from a cell could be transmitted to the ECM 
environment. Cells can change integrin dimer structures that alter the similarity of the receptor and ligands 
[62, 63]. 
When they have low similarity they are in the inactive state in which intra-membrane bonds keep β-
subunit in a stable tilted position towards α-subunit, whereas the active receptor forms in the high affinity 
of the two, when β-subunit is shifted away from the α-subunit [62]. The integrins’ active or inactive state 
can be affected by some adaptor proteins that are in interaction with the β-integrins [62, 64]. The expression 
level of proteins such as kindling kinases, talin, alpha-actinin, and filamin could change the activation 
process of integrins [64]. In conclusion, the activity of integrins can be influenced from cell signaling as 
much as it can influence cells’ behavior. 
Many of the commonly known functions of integrins are among the important functions that help tumors 
grow aggressively. For example, integrins can promote cell migration and survival through interactions 
with the ECM ligands. It has been shown that integrin receptors α2β1 and α5β1 have a role in promoting 
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colorectal cancer metastasis to the liver, mediated through their interactions with collagen and fibronectin 
[65, 66]. However, some integrins can function as a metastasis promoter or an anti-cancer substance, or 
both in different conditions. For example, α5β1 can also promote cancer invasion and metastasis by 
secreting matrix metaloproteinases (MMPs) and this process can be prevented by another integrin, α4β1, 
which also binds to fibronectins at different site [67, 68]. 
Among all of the positive or negative effects that integrins can have on cancer cells, the effects that 
interactions of integrin and ECM have on cell survival can have very important role in the resistance of 
cancer cells. Anoikis is a form of apoptosis that happens in epithelial cells when they become detached 
from the ECM [69]. Therefore, anoikis that occurs by signaling provided from interactions between integrin 
and ECM can stop tumors from expanding cancer and spreading the cancer cells to other tissues in the body. 
However, cancer cells could reach a protection against other stimulus and find an opportunity to have 
adhesion to ECM and resist the toxicity of chemotherapy agents with cell adhesion-mediated drug 
resistance [70]. For example, it has been shown that resistance to chemotherapy drugs increases when 
multiple myeloma cells are attached to fibronectins [70]. In a study on acute myeloid leukemia (AML) cells 
with exogenous fibronectin showed more resistance to a chemotherapy drug through a PI3K/GSK3β 
pathway that is recognized with the α4β1 and α5β1integrins [71]. In this case, drug efflux pumps were not 
involved in the resistance process of AML cells. AML patients with α4β1-negative tumors had higher 
survival rate without cancer than α4β1-positive patients [71]. In both in vitro and in vivo xenograft 
experiments, it was demonstrated that SN-38 resistant cells had a slower doubling time, a shorter S phase 
and a longer G2 phase fraction [56]. These changes to the cell cycle could affect tumor progression and 
resistance to other antitumor treatments. 
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1.3 Objectives and hypothesis 
The goal of first part of this thesis is to apply proteomic techniques in order to identify differences in the 
proteome of an inducible CHO cell line that can produce higher amounts of mAb with cumate. To 
distinguish between these two cell lines, they are termed low-producer and high-producer cells. In this 
thesis, the inducible CHO cells constructed with the vector containing cDNA of the mAb EG2-hFC1 
produced high levels of mAb with the presence of cumate and very low levels of mAb without cumate. A 
proteomics approach can reveal the possible stresses or cell responses at the protein level when the 
production of a recombinant protein (mAb) is high. This type of analysis can suggest potential targets for 
optimizing the cell inducing technique to gain optimized mAb production. 
The second topic of interest is drug-resistance in human colorectal cancer. A derivative of HT-29 cell 
line with SN-38 resistance was generated by prolonged exposure to SN-38, which is the active metabolite 
of the chemotherapeutic drug irinotecan. The iTRAQ proteomics method was similarly applied to explore 
the changes in the cells that became resistant to the treatment. By exploring the cell proteome, our goal is 
to determine the key pathways and metabolic features that change in CRC cells that become resistant. This 
can help to better elucidate the process by which cancer cells undergo in a path to drug resistance. 
The first chapter of this thesis includes an introduction to the CHO and HT-29 cell lines. Background 
information on the proteomics technique used in this thesis and the methods applied in data analysis are 
described in chapter two, and the results of the analyses are reported and discussed in chapters three and 
four. In this thesis, I report and discuss the proteomic experiments and results of HT-29 cells in comparison 
to HT-29S cells with induced resistance to SN-38. The objective is a quantitative comparison of the whole 
cells’ proteome to discover differentially expressed proteins to understand their role in the development of 
SN-38 resistance in an HT-29 cell line. 
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Chapter 2 
Quantitative Proteomics Methods 
2.1 Introduction  
In this thesis, quantitative proteomic technique by iTRAQ labeling reagents is used to quantitatively 
compare target samples with a set of control samples to understand the intrinsic features of the sample under 
the desired conditions. In one part, we have the inducible CHO cell line CHO-1A7 expressing the 
monoclonal antibody EG2-hFc1 that is generated using lentiviral vectors and the cumate gene-switch; in 
the second analysis, we have the colorectal cancer cell line HT-29 and HT-29S that is resistant to the 
chemotherapy treatment SN-38. In summary, Figure 2.1 shows the workflow of an iTRAQ experiment 
consisting of the sample preparation, labeling steps, and mass spectrometry analysis. 
2.2 iTRAQ Labeling  
The iTRAQ technique has been developed to compare proteins of up to 8 different complex samples. 
Samples can be labeled by iTRAQ reagents and the mixture of labeled proteins can be analyzed 
simultaneously by mass spectrometry methods [72]. This proteomics method enables identification and 
quantitation of peptides/proteins in addition to their post-translational modifications of the samples mixture 
[72]. 
For an iTRAQ experiment four or eight reagents can be used to tag peptide samples. The structure of the 
reagent labels (Figure 2.2) consists of a uniquely charged reporter group that is identifiable in mass 
spectrum, a peptide reactive group that interacts with primary amines, e.g. lysines and peptide N-termini, 
and a neutral balance portion that maintains the overall mass of the reagent molecule and falls off in the 
fragmentation step [72]. 
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Figure 2.1: The workflow of sample preparation for an iTRAQ experiment. Samples are 
four control and four treated replicates of cells. After protein extraction and digestion following 
the filter-aided sample preparation method, samples are labeled with 8 iTRAQ reagents and the 
peptide pool is prepared for mass spectrometry. Finally, data analysis is done for identification 
and quantitation of the proteins. 
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Figure 2.2: The iTRAQ reagent structure. Four iTRAQ 4-plex reagents have the same total 
mass of 145 Da with reporter group mass of 114-117 Da and balance group with mass 31-28 Da 
[73]. The total mass of isobaric tags among all 8-plex reagents is 305 Da, reporter groups have 113-
119 and 121 Da mass and balance groups have a mass of 192-186, and 184 Da. 
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In an iTRAQ experiment, equal amounts of total peptide from each sample is labeled by 8 labeling agents 
according to iTRAQ manufacturer’s protocol. To label the samples efficiently, pH has to be adjusted and 
kept between 7.5 and 8.5. The labeled peptide samples are mixed and prepared for mass spectrometry 
analysis by a peptide clean-up step. Then, the sample will be sent to a mass spectrometry facility for analysis 
and generating MS raw data that will be used in further data analysis. 
2.2.4 Mass spectrometry data analysis 
Samples consisting of pooled, iTRAQ-labeled peptides were analyzed using a Q-Exactive mass 
spectrometer at the SPARC BioCentre (SickKids hospital, Toronto). Raw MS and MS/MS data includes 
the data from ionized peptides based on their mass to charge ratio (m/z) and the masses of ions made from 
fragmented peptides on the spectra. In order to identify peptide sequences from the complex mass spectra, 
expected ionization and fragmentation patterns for peptide sequences can be identified and compared using 
MS software. The fragment ions observed in the spectra are made based on the peptide sequences, the ion’s 
internal energy, and the charge. The mechanism of fragmentation of protonated peptides is well known. 
The fragment ions that carry the charge on N-terminal are called a, b, or c, and when the charge is on the 
C-terminal, they are named as x, y, or z (Figure 2.3) [74]. Ions b and y are the most stable ones appearing 
as peaks in the spectra. These peaks represent specific masses in the spectra and can be searched through 
protein databases with predicted masses of fragmented peptides to identify peptide sequences in the 
samples. 
The data produced by a combination of LC and MS/MS can be seen as thousands of points represented 
by retention time (RT), intensity, and mass to charge ratio (m/z). The process of inferring proteins sequences 
from the MS/MS data can be done by several software packages. PEAKS Studio 7.5 (Bioinformatics 
Solutions Inc., Waterloo, ON, Canada) is a powerful software tool that incorporates a de novo sequencing 
method into its database search algorithm. This algorithm achieves higher accuracy and sensitivity, and 
better time efficiency than other common software packages [75]. PEAKS Studio 7.5 is used for 
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identification and quantification of proteins in the mass spectrometry data. The general workflow of MS 
data analysis in PEAKS is represented in Figure 2.4. 
PEAKS includes a de novo sequencing algorithm that can identify proteins independently from the 
sequence database. De novo means from the beginning in general usage; it means making computational 
predictions using a model without incorporating any of the existing data. De novo peptide sequencing is 
allocation of fragment ions from the tandem mass spectrum. This de novo algorithm finds the best set of 
amino acid sequences among all of the different possible arrangements, and allows the software to cover 
the new peptides not included in databases of known proteins. PEAKS performs these computations 
efficiently using an advanced dynamic programming algorithm [75]. The de novo algorithm determines a 
score for each peptide sequence that represents the best match for the b and y peaks in the spectrum [75]. 
Then, the algorithm reports the distribution of average local confidence scores for each identified peptide. 
The average local confidence is the total local confidence divided by the number of amino acids in the 
peptide sequence, independent of peptides’ size. 
The target-decoy method is widely used to estimate the identification quality as a false discovery rate. 
The software searches the concatenation of a target and a decoy database that have the same sizes. The false 
search results should become evenly distributed in target and decoy, when the decoy is constructed 
correctly. We can estimate the FDR since all the decoys are false, FDR will be estimated as the ratio of the 
decoy hits over the target hits.  
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Figure 2.3: Fragmentation ions in peptide backbone. In peptide backbone fragmentation a, b, and 
c ions extend from the amino terminus, and x, y, and z ions extend from the carboxyl terminus [76]. 
 
Figure 2.4: The overall workflow of raw MS data analysis using PEAKS 
(http://www.bioinfor.com/peaks-studio) 
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PEAKS database search tool (PEAKS DB) incorporates de novo sequencing results into the database 
search to optimally explain the spectrum. Therefore, PEAKS DB works efficiently by limiting the search 
items with shortlists of proteins and peptides based on de novo results. The search scoring function finds 
the similarities between de novo results and the database; it also normalizes them to be comparable across 
the spectra. Then it confirms the results with a false discovery rate (FDR) threshold chosen by users, such 
as 1% false positive identifications. Finally, using peptides with the highest confidence score, it infers and 
groups protein sequences [77]. 
The iTRAQ method from PEAKS Q module was used for protein quantification analysis. This module 
detects features of the mass spectrometry data and calculates each labeled peptide ratio based on peak areas 
in the spectra. The algorithm uses total intensity of the top-3 unique peptides for each protein and 
consequently makes a clustered set of proteins with the detected raw intensities and ratios. 
2.2.5 Differential expression analysis 
Data normalization is necessary to ensure bias-free comparison of the intensities across different labeled 
samples. Several normalization methods that are not based on internal standards have been used for MS 
data, including quantile normalization, lowess, and global scaling [78]. Quantile normalization is a 
frequently used algorithm with this type of data, which sorts and scales the data to match a certain quantile 
among samples. 
Quantile has a simple and quick algorithm that uses the complete raw intensities data, to create the 
normalization relations and could be applied to the data using R bioconductor packages, e.g. “limma” or 
“preprocessCore” [79, 80]. This normalization method aligns the distribution of intensities for each column 
across the dataset, or equivalently across samples so that they are similar. The idea is that the quantile-
quantile plot shows the distribution of two sets of data as a straight diagonal line. It can be extended to n 
vectors of data to have the same distribution. In this dataset there are 8 groups of data from each samples 
labeled with a unique iTRAQ reagent. To transform the quantiles, projection of quantiles onto the unit 
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diagonal should be performed. This procedure is taking the mean quantile and replacing it as the value of 
the data in original raw dataset [79]. 
After normalizing the data from the eight labeled samples, variation between data from the two 
conditions should be explained. If the data cannot be explained by random variation, we conclude that that 
the two distributions have some significant differences present and it is not just through random chance. 
The test of significance is a method of statistical inference performed to accept or reject a claim based on 
sample data. In order to compare the abundances of proteins of the two cell lines, a hypothesis test should 
be implemented. An unpaired two sample t-test can be performed, testing the null hypothesis states that the 
averages of the intensities of samples are equal to each other. The test generates a p-value that shows the 
probability of the sample mean difference in protein expression of the two groups would be the same as or 
larger than the actual observation, when the null hypothesis is true (there is no change between the groups). 
Therefore, the lower the p-values are, the less likely that the mean difference occurred by chance alone and 
the difference is significant. 
The result can be one of the following four situations, when a null hypothesis is true and test has not 
rejected (not significant), when the null is true but t-test rejected it (type I error), when a null hypothesis is 
false and test rejected the null (significant), and it is false but the test has not rejected the null (type II error). 
To generate meaningful results, the statistical power is a key prerequisite in a successful quantitative study. 
When we have β as the false-negative rate, the statistical power is 1-β. This is the probability that the result 
is a type II error [81]. 
There are multiple comparisons and null hypothesis tests stating that the averages of the intensities of 
each sample group are equal to each other. By testing each hypotheses separately with a significance level 
α=0.05, commonly chosen for two standard deviations from the mean, there is a high chance of error in 
several hypothesis tests. The probability of observing a significant result by only chance can be high when 
n is a large number: 
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P = 1-(1- α)n ≈ nα 
A multiple testing correction procedure is required to adjust a suitable statistical confidence measures 
based on the number of hypothesis tests. One way is decreasing the error threshold for each test by the 
number of tests to have an overall α with the desired limit. This correction, the Bonferroni technique, 
requires α/n for each test to result in an overall of α allowable error for n number of comparisons. This 
method is too strict for high-throughput experimental data and has been replaced by Benjamini-Hochberg 
FDR method or similar techniques to control the false discovery rate [82]. 
The False Discovery Rate (FDR) is the expected proportion of false positives within the significant tests 
and estimates the rejection region. Benjamini-Hochberg method for a given q, say q = 0.05 or q = 0.10, 
calculates linear step-up values as expected to be the significant p-values. While the p-value is lower than 
the expected value the tests are rejected. The Benjamini-Hochberg procedure is as follows, 
Pi : P1 ≤ P2 ≤…≤ Pm , (m: number of tests)  
k = Max(i, such that Pi ≤ 
𝑖
𝑚
𝑞 ) 
The procedure rejects null hypotheses Pi to Pk, produces a list of significant tests. 
Since there have been many studies regarding the problem of finding differentially expressed genes in 
microarray experiments, many resources are available for the statistical analysis. R programming packages 
R stats, multtest, and LIMMA library (Linear Models for Microarray Data, v 3.22.1) [80] of the 
bioconductor package [83] are used for statistical analysis. 
2.2.6 Functional analysis of differentially expressed proteins 
After analysis and comparing the protein expressions with a suitable significance level, a list of proteins 
will be identified with significant differential expressions. Therefore, studying their cellular functions and 
molecular mechanisms is essential. For this purpose bioinformatics tools and databases, such as COG, 
KEGG, DAVID, and GO have been developed that help in functional analysis of lists of genes and proteins. 
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This level of analysis is similar to genomics data annotation, so gene ontology tools can be useful. The 
database for annotation, visualization, and integrated discovery, DAVID, [84] is an integrated analytical 
and biological knowledge-based tool is used to extract biological meanings from gene or protein lists. 
DAVID can provide enrichment categories of genes in the list. 
DAVID is a web-based bioinformatics tool available at http://david.abcc.ncifcrf.gov/ is developed to 
annotate large gene lists into meaningful biological information [85, 86]. It is designed to map the gene list 
to their associated biological annotation or gene ontology terms, and to identify those genes that are 
enriched (overrepresented) [85]. In addition, DAVID clusters related terms into groups to facilitate the issue 
of redundancy in biological annotation terms [86]. The output includes a p-value calculated by a modified 
Fisher’s exact test (EASE score), which shows the significance of enrichment of terms. The threshold for 
enrichment score is 1.3, which is equivalent to 0.05 [85]. 
The list of genes corresponding to differentially expressed proteins is subjected to DAVID’s analytical 
modules to identify functional groups within enriched genes. We can explore possible links between 
function and the cells productivity, and more thoroughly understand the cells response to the treatment. In 
case that the cells were under a stress or had an abnormal condition, genes that relate to the process in the 
cells would be identified in the enriched groups. Then, the enrichment score of gene groups is used for 
ranking the importance of annotation terms [85]. Using DAVID 6.8 analytical tools, we can identify the 
gene enrichment in the biological process and functions in gene ontology, and the KEGG pathway database 
most relevant biological terms associated with the gene list. 
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Chapter 3 
Comparative proteomic analysis of CHO cells 
3.1 Introduction 
Chinese hamster ovary (CHO) cells are a suitable host for production of therapeutic mAbs that are complex 
multimeric and glycosylated proteins [7]. Typically, a population of recombinant CHO cells clones with a 
range of specific productivity is generated by transfection of cells with the gene of interest, followed by 
clonal selection, and amplification. This process for having the best-performing clones is time-consuming 
(taking 4 to 8 months) and costly. Expression systems using strong viral promoters helps in improving mAb 
production. The inducible CHO cell line in this study was developed using CR5 promoter in lentiviral 
vectors [26] with cumate gene switch for inducing high levels of mAb secretion [26, 27]. This mAb product 
is used in treating a variety of cancers because it targets cells that express epidermal growth factor receptor 
(EGFR). EGFR is a tyrosine kinase receptor that plays a role in the control of important cellular processes 
such as angiogenesis, cell growth and proliferation. Various types of human cancer cells have mutations in 
the EGFR gene [87]. 
Transduction of cell lines with lentiviral vectors is a gene expression system for optimizing the 
production of recombinant antibodies [26]. One of the key elements of a good expression system is the use 
of a strong promoter. An inducible system with the cumate gene switch promoter (CR5) with the cumate 
transactivator (cTA) and the reverse cTA promotes expression of the gene of interest (explained in details 
in section 1.1.6) [26, 27].  
We used a proteomics approach in this thesis to investigate the possible stress or cell responses in the 
inducible cells when they produce high amounts of MAb. Using the iTRAQ proteomics technique, we 
quantitatively compare the cells at the protein expression level. The CHO cell line was generated by 
transducing the cells with lentiviral vectors including cumate gene switch promoter elements in Dr. 
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Durocher`s lab. By adding the cumate treatment these cells were able to have close to 6 fold change increase 
in mAb production. The proteomic analysis helps us to compare protein expression within induced and 
uninduced cells and find possible targets for optimizing the technique for optimizing mAb production. 
3.2 Methods 
Four control replicates of inducible cell line were cultured, and another four replicates were treated with 
cumate to increase mAb production. The collected cells were subjected to cell lysis, protein extraction and 
digestion. These eight peptide samples were labeled using 8-plex iTRAQ isobaric labels for differential 
expression analysis. Mass spectrometry (MS) was performed and I used the generated MS data for protein 
identification and quantitation, and statistical analysis of protein expression. In this chapter, the results of 
the data analysis is presented and discussed. 
Using the iTRAQ method, protein expression levels of eight samples can be compared in one mass 
spectrometry run. The iTRAQ reagents label lysine residues and all free amino terminal groups of peptides 
via covalently bound tags. In the CID stage of tandem mass spectrometry, the balance group of the tags is 
lost, and in the analysis of the peptide fragmentation (MS/MS) the reporter groups are detected. The MS/MS 
spectra includes tags from all samples containing the given peptide, and contributions of each sample is 
measured by the reporter ion peak’s intensity. In this study, the spectrum is analyzed using PEAKS Studio 
7.5 and then peptides and proteins are quantified to identify the differentially expressed proteins. 
3.2.1 Cell culture 
The cell lines were developed using a transduction system by lentiviral vectors coupled with the cumate 
gene-switch [26]. Transduced CHO samples were obtained after treating with cumate and a control set 
without treatment. The mAb titer in the culture media was measured at the harvest time and cells were 
frozen at -80°C prior to iTRAQ experiment. Protein samples were extracted from whole cell lysates, then 
proteins were digested and peptides were labeled using iTRAQ 8-plex reagents.  
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Cell lines were kindly provided by Dr. Yves Durocher at the Biotechnology Research Institute (BRI) 
(Montréal, Canada). The CHO-1A7 cell line was engineered for the stable expression of the chimeric heavy 
chain antibody EG2-hFc1. The process of the cell culture and induction was contributed by Adeline Poulain 
from Dr. Yves Durocher's lab [88]. The replicates of cell line that were developed from a stable transduction 
LV system, were cultured in suspension with working volumes of 250ml shaker flasks. Cells were incubated 
at 5% CO2 in a humid environment at 32° Celsius. Four of these batches were treated with 2ug/ml cumate 
5 days post-transduction (6-9 million cells/ml). The cumate induced CHO cells and control samples were 
harvested at the exponential phase of growth 5 days after the treatment, and the monoclonal antibody 
product of each replicate was measured. Cell pellets were stored at -80°C prior to proteomic analysis. 
3.2.2 Protein sample preparation and labeling 
In mass spectrometry experiments, many detergents and common chemicals are incompatible with 
instruments and can introduce contamination that will distort the results. Polyethyleneglycol from plastic 
ware and keratins from skin are the most abundant contaminants of protein samples. To prevent 
contamination procedures were done in biosafety cabinet. In addition, in all steps of the procedure HPLC-
grade solvents were used and all pipette tips and tubes were rinsed twice with 100% methanol and let dry 
overnight in the biosafety cabinet. 
Whole cell protein extraction from cell pellets that were stored at -80°C was started after quickly thawing 
the samples and lysing them. Lysis buffer constitutes of 1% Triton X-100, 100 mM HEPES (238.3 g/mol) 
adjusted to pH 7.5 by NaOH/HCl, 50 mM tris(2-carboxyethyl)phosphine (TCEP from iTRAQ kit), and 5 ul 
protease inhibitor cocktail (Sigma, P8340) was prepared and for each sample 700 ul of the lysis buffer was 
used for 30 min at 4°C. Once the cells are disrupted proteases can degrade proteins; therefore protease 
inhibitors must be in the lysis buffer. Also, TCEP should be added in the lysis buffer as the reducing agent 
as this agent is necessary for cleaving disulfide bonds, helping to keep proteins stable and to prevent protein 
aggregates. TCEP replaces the commonly used reducing agent dithiothreitol (DTT) with several advantages 
[89], such as a wider effective pH range, more hydrophilic characteristics, stability and reactivity for a 
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longer time at room temperature as it is more resistant to oxidation in air. These features ensure the 
effectiveness of the reducing agent on the protein samples. 
Next, the cell lysates were centrifuged at 10,000x g to extract the supernatant. After each step during the 
protocol the protein concentration was measured by Bio-Rad microplate protein assay (Bio-Rad 
Laboratories Ltd., Mississauga, Canada). This assay is based on Bradford method [90], which requires 
constructing a standard curve at each protein assay run. Bovine serum albumin (BSA) (Sigma, ON, Canada) 
with 0.0, 0.2, 0.4, 0.6, 0.8, and 1.0 mg/ml concentration was used for the linear standard curve. The 
corresponding spectrophotometer absorbance was read at 595 nm by a Multiskan UV microplate 
spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA). The protein samples were diluted at 
each step to prevent any interference of the buffers with the Bradford agent and to increase sensitivity of 
the measurement at high protein concentrations. 
Following the measurement of protein concentration, from each sample 1 mg of protein lysates were 
precipitated using a Calbiochem ProteoExtract kit (Cat# 539180, EMD Millipore). The precipitation agent 
was prepared according to the kit’s instructions and the wash solution was prepared by adding 150ml high 
quality ethanol to the bottle of wash solution provided in the kit. These agents were stored and chilled 
at -20°C prior to precipitating the samples. From each sample, 1 mg of the protein lysate was precipitated 
by addition of a 4x volume of the precipitant agent following the manufacturer’s protocol. Samples were 
incubated at -20°C for 60 minutes, and then proteins were pelleted by centrifugation at 10,000x g at room 
temperature and the supernatant was discarded. Following the Calbiochem protocol, pellets of proteins were 
washed 2 times with 500µl of cold (-20°C) wash solution.  
Subsequently, the precipitated protein samples were re-suspended in UA buffer, containing 8M Urea and 
100mM HEPES at pH 8.6. At this step, another Bradford microplate assay was performed to measure the 
concentration of solubilized proteins. From each sample 250µg of completely solubilized proteins was used 
in filter-aided protein sample preparation procedure [91]. 
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In this study, after testing two 3k and 10k filters with the protein samples, for the best results I chose to 
use Amicon Ultra centrifugal filters with relative molecular mass cut-off of 3k. In the filter-aided sample 
preparation the whole proteome is completely solubilized in chaotropic detergents, then the buffer is 
exchanged in the filter purification step [92]. 
Next, proteins were alkylated to block cysteines by adding 50mM iodoacetamide (IAM) to the UA buffer. 
Alkylation was performed with a limited quantity of IAM and the buffer was slightly alkaline with pH of 
approximately 8 to make sure that is not affecting residues other than cysteines. Samples were in 0.5 M 
triethylammonium bicarbonate pH 8.5 (TEAB) buffer prior to digestion with lyophilized trypsin. In-filter 
digestion was performed using 1:50 trypsin to protein ratio. Samples were trypsinized for approximately 8 
hours at 37 °C. For deactivating trypsin’s activity and concentrating the peptides, samples were dried using 
Thermo Scientific Savant Speed Vac vacuum centrifuge and re-suspended in 30uL TEAB. Finally, prior to 
labeling, peptide concentration of samples was estimated using the A280 method [93] on a NanoDrop™ 
2000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA). 
Equal amounts of peptide from each sample were labeled using the eight labeling agents according to 
iTRAQ manufacturer’s protocol. To label the samples efficiently, pH was verified using Hydrion pH papers 
and adjusted to be between 7.5 and 8.5. The labeled peptide samples were combined into one tube and dried 
using vacuum centrifuge in a Speed Vac® from Savant (Thermo Fisher Scientific, Waltham, MA, USA). 
Then, the dried sample was resuspended in the ACN buffer, comprised of 300ul of 5% acetonitrile, 0.1% 
formic acid for peptide clean up step. 
Peptide clean up was performed using Empore™ C18 solid phase extraction cartridge (4115SD) 
according to the cartridge column’s protocol. The washing step was done by adding deionized water and 
0.1% formic acid solution to the sample and letting it pass through the particle bed of the C18 cartridge by 
gravity. After 3 times repeating the washing step, sample was eluted in two steps of adding 200ul buffer of 
70% acetonitrile and 0.1% formic acid to the cartridge. Peptide concentration was estimated using 
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Nanodrop, and mass spectrometry analysis was performed at the mass spectrometry facility of SPARC 
BioCentre at the SickKids hospital, Toronto, as described in chapter 2. 
3.2.3 Mass spectrometry data analysis  
The raw mass spectrometry data is processed by PEAKS Studio. First, the de novo analysis of the software 
identifies the peptide sequences, and using the results the PEAKS database search tool searches through the 
database that we constructed for the dataset. After filtering the results of protein identification analysis, 
PEAKS quantitation tool is used to calculate the expression data for the proteins. The differential expression 
analysis of the dataset is performed using R packages stats within the CRAN project (R Core Team, 
https://cran.r-project.org/) and limma within the Bioconductor project 
(https://bioconductor.org/packages/release/bioc/html/limma.html) [80, 94]. 
Known post translational modifications were selected in PEAKS to assist the accurate identification of 
sequences. Carbamidomethylation of cysteines (+57.02 Da) and iTRAQ modified N-terminal and lysine-
side chain of tryptic peptides (+304.2 Da) were selected as fixed modifications; oxidation of methionine 
(+15.99 Da) and iTRAQ modified tyrosine (+304.2 Da) were set as variable modifications in the analysis. 
Only 1 missed cleavage was allowed, majority of peptides were identified with no missed cleavage. 
3.3 Results 
Following four days of cumate treatment cells were harvested. Corresponding EG2 quantification data was 
provided by Dr. Durocher, Biotechnology Research Institute (BRI), Montréal, Canada. The expression level 
of mAb in the induced samples was increased by 5.7 fold change on average (Table 3.1). 
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Table 3.1: mAb titers of CHO cell line replicates in the two treatment conditions 
Replicates of Inducible Cells 
CHOBRI55E1-EG2-Fc-X1 
Cumate 
treatment 
mAb Titer (mg/l) Fold 
change 
Control 1 - 51  
Control 2 - 48  
Control 3 - 42  
Control 4 - 51  
1 + 295 5.8 
2 + 283 5.9 
3 + 266 6.3 
4 + 254 5.0 
3.3.1 Protein identification and quantitation by PEAKS 
The raw data results from the LC-MS/MS system were analyzed by PEAKS Studio 7.5 (Bioinformatics 
Solutions Inc.). From the total of 84,416 tandem mass spectrometry scans, 19,544 peptide sequences were 
identified after filtering by the de novo sequencing algorithm. Figure 3.1 represents the average local 
confidence scores of peptides vs. mass errors in ppm. The mass error of the peptides as stated in PEAKS 
user manual is calculated based on “a ratio of observed mass error (difference between observed mass and 
theoretical mass) and the theoretical mass and is expressed in ppm” [75].  
The Refseq protein database from chogenome.org with the addition of the produced antibody sequence 
with a total of 22,527 entries was used in PEAKS DB search. PEAKS database search could match 12,771 
peptide sequences with minimum 15 confidence score (initial cutoff for peptide matches). The reported 
result with a FDR cut-off at 5% included 11,523 peptide sequences and 3,410 proteins identified in the 
search against this database. Figure 3.2 shows the PSM (peptide spectrum match) score distribution. We 
observe very few decoy matches in the region with high scores, this demonstrates the high confidence in 
the search result and the peptide -10lgP score threshold is of high confidence. The software estimated FDR 
using the tartget-decoy method and the figure 3.3 shows the FDR curve for the PSMs. 
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Figure 3.1: Average local confidence (ALC) scores of de novo peptides are plotted against mass 
errors of the identified peptides in ppm. Peptides with ALC scores above 30 was used in the next steps 
of analysis Mass errors (in ppm) of the identified peptides are plotted against their ALC scores.  
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Figure 3.2: The histogram of PEAKS peptide scores. Histogram shows the number of peptide-
spectrum matches with the corresponding peptide score calculated in the PEAKS DB search. Using 
the target-decoy method, decoy hits shown in brown and target hits in blue, the FDR is estimated by 
the software. 
 
 
Figure 3.3: The FDR curve for the identified peptide spectrum matches. The figure shows the FDR 
value corresponding with the number of PSMs that are kept in the final result.  
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3.3.2 Differential expression analysis 
Raw intensities of all proteins were exported from PEAKS software. The software represents protein 
expressions as an intensity value for each label. Based on our experimental design, data was separated into 
two groups of control samples and samples with cumate treatment. To reduce bias due to differences in 
sequencing depth between samples, the expression values were subjected to quantile normalization as 
described in section 2.2.5. Once the data is grouped and normalized, they were compared using unpaired 
student’s t-test with unequal variance in R stats and limma package [80]. Next, threshold for significant 
differences was set by applying the Benjamini-Hochberg correction method to the generated list of p-values 
[82]. Also, fold changes of proteins were calculated and added to the table. 
In protein identification by PEAKS, groups of proteins are identified by a common set of peptides. In 
this dataset we had a total number of 3,410 proteins identified. The protein groups contain similar 
sequences; therefore, the top protein from each group that has the highest score and number of peptides 
identified is used in the data analysis steps; at the end 1,616 proteins which have a valid expression value 
for all of the samples (more than zero) were tested. For a more clear representation and identifying 
significantly regulated proteins with large differences, a logarithmic scale of p-values was plotted versus 
fold-change, known as the volcano plot (Figure 3.5). Among this set of unique protein sequences 82 
proteins had differences with raw p-values lower than 0.05 (Appendix A). Then we removed proteins that 
had minimal change in expression levels in all samples with a fold-change threshold close to 1 (-0.1< 
logFC <0.1). Using Benjamini-Hochberg method for multiple hypotheses testing correction with q equal 
to 0.05, the p-value threshold was set to 2.6e-04 (0.00026), which will not accept any of the proteins as a 
significant result (Figure 3.4). FDR level with q as 0.25 will set the p-value threshold to 0.004 and 9 top 
proteins will be accepted with a significant difference. Table 3.2 shows the proteins with the lowest p-
values which have a high increasing or decreasing fold change among the list; appendix A provides the 
complete list of 82 proteins with p-values below 0.05. The top protein that is accepted in the hypothesis 
testing is the mAb sequence produced by the cells. Based on the experimental data, the antibody titer in 
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the culture media had an average increase of 5.7 fold, and the proteomic data is consistent with this, as the 
mAb had almost a 3 fold-change in the whole cell proteome.  
 
 
Figure 3.4: Sorted p-values vs. BH adjusted values. The blue curve represents the p-values lower 
than 0.05 and the red is the Benjamini-Hochberg adjusted values. The distribution of p-values shows 
that there are not any significant results with this threshold. 
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Figure 3.5: Volcano plot of CHO protein expression data. The negative logarithm of p-value vs. log 
fold-change of CHO proteins. The points shown in red color are sequences of the mAb product and 
the sequence of antibody’s heavy-chain. 
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Table 3.2: List of candidate genes with the highest fold-change showing the highest increasing/decreasing 
expression levels in the high-producer CHO cells and the significant p-values with two FDR cut-offs at 
5% and 25%. Table includes the log fold-changes above 0.2 and below -0.2 in addition to the significant 
p-values with FDR 25%, although they have small changes. 
Gene Fold 
Change 
log 
FC 
p-value Significant 
FDR (5%) 
Significant 
FDR 
(25%) 
Protein ID Protein 
EG2-hFc1 2.83 1.50 0.00003 Y Y mAb 
sequence 
EG2-hFc1 mAb product 
TRMT112 1.26 0.33 0.001 N Y 354498436 tRNA methyltransferase 
PPP1R12A 0.94 -0.09 0.001 N Y 354492600 protein phosphatase 1 regulatory 
subunit 12A-like 
RSP7 1.12 0.16 0.002 N Y 354495303 40S ribosomal protein S7-like 
MRP-L55 0.74 -0.43 0.002 N Y 354482471 Ribosomal protein L55  
mitochondrial  
GSTP1 0.88 -0.18 0.002 N Y 350537543 glutathione S-transferase P 1 
FKB11 1.20 0.26 0.003 N Y 354497358 Peptidyl-prolyl cis-trans isomerase  
Lsm3 0.87 -0.20 0.003 N Y 354465501 snRNA-associated Sm-like 
PUF60 0.91 -0.14 0.004 N Y 354491098 poly(U)-binding-splicing factor 
PUF60-like  
TRA2B 1.22 0.29 0.006 N N 354484188 Splicing factor 
GANAB 1.15 0.20 0.006 N N 354493306 Glucosidase alpha neutral  
LAMC1 0.82 -0.29 0.006 N N 354481424 Laminin subunit gamma-1 
VIM 0.83 -0.27 0.008 N N 354482483 Vimentin  
HN1L  0.84 -0.25 0.009 N N 354466573 Hematological neurological 
expressed 1 
RPS6  1.16 0.21 0.012 N N 354507225 Ribosomal protein S6 
GLUL 1.22 0.29 0.023 N N 354481440 Glutamine synthetase  
UBE2O 0.83 -0.27 0.023 N N 354489489 Ubiquitin-conjugating enzyme 
E2O 
IGF2BP2 0.83 -0.27 0.025 N N 354484186 mRNA-binding protein 2 
CN166 0.86 -0.22 0.028 N N 354477974 RNA-binding protein 
Slc27a4 0.85 -0.23 0.032 N N 354499491 Long-chain fatty acid transport 
Icam1 0.86 -0.22 0.033 N N 350539683 Intercellular adhesion molecule 1 
HSPG2 0.85 -0.23 0.040 N N 354483018 Basement membrane-specific 
heparan sulfate proteoglycan  
CTSM 0.85 -0.23 0.042 N N 354468711 Cathepsin M 
CC115 0.86 -0.22 0.044 N N 354491621 Coiled-coil domain 
GALM 0.83 -0.27 0.049 N N 354488923 Aldose 1-epimerase 
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3.3.3 Functional analysis 
The top protein with the highest fold-change is the multifunctional methyltransferase (trmt112). It is 
involved in methylation of proteins and tRNAs, and heterodimers of this methyltransferase subunit with 
some other methyltransferases function in efficient translation termination by catalyzing a methylation in 
translation factor 1. Transformer-2 beta (TRA2B) is a splicing factor and also reacts in the translation 
process, particularly in controlling pre-mRNA splicing. Its activity can suppress or cause exon inclusion. 
These splicing patterns can change by acting as antagonist of other splicing regulators, like RNA binding 
motif protein. 
Among other proteins with increasing expression level, GLUL is the protein-coding gene for glutamine 
synthetase or glutamate-ammonia ligase. Amino acid synthesis and glutamine uptake are among the related 
pathways to GLUL. In the conditions that cells produce high levels of antibody the metabolism and energy 
uptake is expected to be higher.  
The alpha subunit of glycosidase II (Ganab) codes a protein that has a role in protein folding and quality 
control. In the process of translation in endoplasmic reticulum, this enzyme involves in cleaving glucose 
residues from immature glycoproteins. The presence of this protein is required in modifying glycosylation 
patterns since it is involved in N-glycan metabolism. The peptidyl-prolyl cis-trans isomerase, expressed by 
the gene FKB11, accelerates the folding process of proteins during protein synthesis. These processes in 
cells with a high rate of mAb production, which have large and complex structures to fold, are expected to 
be increased.   
Among the proteins showing a decrease in abundance are vimentins. They are intermediate filaments 
attached to the nucleus, endoplasmic reticulum, and mitochondria. This protein plays a major role in 
cytoskeletal structure of a cell and along with other filaments, such as MYH10, vimentin involves in 
stabilizing collagen mRNAs as well [95].  
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Laminin gamma1 (LAMc1) is one of the chains in the extracellular matrix glycoprotein that is involved 
in biological processes, such as cell signaling, cell adhesion and migration. Heparan sulfate proteoglycan-
2 (HSPG2) is a proteoglycan that binds many extracellular components and surface molecules. Both of 
these proteins that are involved in cell signaling and adhesion had slightly lower expression levels in high-
producer cells, although without a significant p-value. 
Although individual genes were not strongly supported, it is possible to look for enriched function within 
the identified gene list as a group. The list of genes in table 3.2 and from the list of all proteins with raw p-
value below 0.05, a list of the genes with down-regulated protein expression, as well as a list of the genes 
with up-regulated protein expression values was uploaded on DAVID analysis tool. In the gene list manager 
section, Chinese hamster (Cricetulus griseus) was selected as the species and gene population background. 
If DAVID knowledgebase did not have a gene’s identifiers for Chinese hamster and their biological 
annotations the mouse data was used instead. In the functional analysis of the list, available information of 
mouse homolog was used. Therefore, the annotations were limited to the two species Chinese hamster 
(Cricetulus griseus) and mouse (Mus musculus) selected in the gene enrichment analysis. 
In the analysis reports from DAVID, no molecular function category was identified to be significantly 
enriched in the gene list. The biological processes and molecular functions commonly shared among the 
candidate gene list were the RNA splicing factors, RNA splicing via spliceosome and transesterification 
reaction. However, the terms were not significantly enriched above the threshold of 1.3 enrichment score 
(Table 3.3). 
Similarly, using the two lists of genes with positive and negative fold-changes and raw p-values below 
0.05, the KEGG pathway database search results were reported. Table 3.4 is a list of the pathways with 
significant enrichment scores using the gene list with negative changes. No pathways were enriched in the 
analysis of the list of genes with positive fold-changes. Two KEGG pathways were also identified with 
high enrichment scores, ECM-receptor interaction (cge04512) and glyoxylate and dicarbozylate 
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metabolism (cge00630). In the former pathway all the genes in the list had negative fold-changes LAMC1, 
COL6A, CD44, FN1, ITGA5. LAMC1 had the largest change, -0.29 fold-change, which had the lowest 
fold-change and p-value among the involved genes. The laminin gamma 1 is a subunit of the extracellular 
matrix glycoprotein. In the second identified KEGG pathway three genes were listed that are involved in 
the biosynthesis of glycoxylate and carbohydrates pathway. These genes had very small changes although 
glutamine synthetase (GLUL) had a 0.28 fold-change increase in the high-producer cells. Since this protein 
is also involved in the synthesis of amino acids and glutamine uptake, the increase in the induced cell line 
is expected.  
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Table 3.3: Molecular functions of the table 3.2 gene list 
Molecular Function Genes 
RNA binding LSM3 
Catalytic activity , Hydrolase activity Ganab 
Cysteine-type endopeptidase activity Ctsm 
Aldose 1-epimerase activity GALM 
Nucleotide binding IGF2BP2, TRA2B, Ube2o, Slc27a4 
Integrin binding ICAM1 
Extracellular matrix structural constituent lamc1 
Protease binding Hspg2 
mRNA binding, structural constituent of ribosome RPS6 
Protein methyltransferase activity TRMT112 
Glycoprotein binding, structural molecule activity VIM 
 
Table 3.4: KEGG pathway database search results. The gene list of proteins with a negative fold-change 
was used in DAVID analysis tool. 
Term Genes 
Fold 
Enrichment 
Benjamini 
cge04512 
ECM-receptor interaction 
CD44, ITGA5, 
COL6A2, COL6A1, 
LAMC1, FN1 
10.5 2.4E-02 
cge00630 
Glyoxylate and dicarboxylate metabolism 
LOC100760000, 
GLUL, GCSH 
20.3 4.7E-02 
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3.4 Discussion 
In this work a quantitative proteomic analysis of inducible CHO cells with cumate gene switch was 
performed. The cell line produces the MAb EG2-hFc1 using a CR5 promoter and cumate gene-switch, and 
could produce over 200ug/ml of mAb in the presence of cumate. With the presence of cumate in cell culture 
medium, these CHO cells were able to produce almost 6 times the amount of mAb produced by uninduced 
cells. Baseline production of MAb without induction is somewhat higher than expected at 48 ug/ml, 
indicating a reasonable amount of ‘leakage’ with this promoter system. In this study we were aiming to 
capture the differences in proteome level between these two different conditions. Our goal is to show 
whether producing high amounts of mAb is putting cells under a significant stress or if this expression 
system has the potential to generate a stable cell line with higher amounts of mAb being produced. 
Using the iTRAQ 8-plex reagents and LC-MS/MS analysis, expression levels of over a thousand unique 
proteins were identified. In this analysis 82 proteins had a p-value lower than 0.05 but by performing the 
FDR test at q=0.25, only nine proteins were identified as having statistically significant changes. Of these, 
we would expect two to be false positives. The highest fold-changes are observed in proteins involved in 
protein processing and RNA binding and splicing. As shown in table 3.3, there are enzymes involved in 
metabolic pathways, precursor metabolites and some are related to energy uptake in CHO. 
Knowing that producing high amounts of protein can put cells under increased stress [32], we were 
expecting that some of the identified differentially regulated proteins may be involved in stress response 
processes. For example, Meleady et al. 2012 in a proteomics study found heat shock proteins and proteins 
involved in the response to oxidative stress are changing in high producer cells [30]. 
Although the cumate induced cell line produced higher mAbs titers on average, we did not identify any 
known stress response proteins with statistically significant changes in abundance. The number of replicates 
used in this study was quite low with four treatments and four controls, so increasing the number of 
replicates would likely result in increased size of dataset and numbers of statistically significant changes.  
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However, based on fold-change there are not many proteins showing large changes in abundance, 
therefore it is likely that the cumate induction system is not causing larger metabolic shifts or stress 
responses within the cell. The lack of large significant differences in the proteome of cells in the two 
conditions can show that the system has generated a stable cell line with higher production capacity. As 
stress responses are not being induced in the cell line there is likely the potential to increase mAb production 
using a stronger promoter system. The lack of stress response suggests that there is excess capacity for 
exogenous protein production that could still be utilized. 
For future studies, considering the scale of culture and production conditions in this experiment, the 
harvesting time, or the complexity and structure of the produced mAb could affect the cells conditions and 
stressors. Therefore, scaling up the production using this cell line might influence the cells and further 
evaluations would be required to analyze the cells condition. Furthermore, cells can be analyzed at several 
intervals during the production process to understand the metabolic changes.  
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Chapter 4 
Comparative proteomics analysis of HT-29 cells 
4.1 Introduction 
Colorectal cancer has one of the highest mortality rates, and is the third leading cause of death in the world 
(American cancer society, CRC facts and figures, 2017). In the recent years, survival rate of CRC has 
increased but this is mostly due to the improvements in the screening and diagnosis of tumors at the early 
stage rather than improvements in therapies. Drug resistance is one of the main reasons for treatment failure 
or patient relapses with metastasis [33]. Irinotecan is one of the main therapeutic agents in treating CRC 
patients as a single agent therapy or in combination therapies. Irinotecan is a camptothecin derivative and 
a member of topoisomerase I inhibitor family of anti-tumor agents. Irinotecan is biologically inactive and 
it needs to be catalyzed to its active metabolite SN-38. 
The target of SN-38, Topoisomerase I, cuts and ligates a DNA strand to change the linking numbers by 
one. It is an essential enzyme for relaxing DNA supercoils that are made during transcription, replication 
processes, and chromatin remodeling. TOP1 inhibitors can interfere during this cleavage reaction; 
interference with the topoisomerases activity results in formation of cleavable complexes with DNA. 
Cellular sensitivity to TOP1 inhibitors could be determined by the deficiencies in both the checkpoint 
pathways and DNA-repair pathways [42]. DNA repair mechanisms and activity of TOP1 enzyme in the 
cells affects inhibitors efficiency [36].  
By exploring the protein expression data, we would like to determine the key pathways and metabolic 
features that have changed in HT-29S cells, to better elucidate the process by which cancer cells undergo 
in a path to drug resistance. To this end HT-29 cells were treated with prolonged exposure to SN-38, which 
made them resistant to the drug. 
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4.2 Methods 
4.2.1 Cell culture 
A derivative of the CRC cell line HT-29 has been generated in Dr. Blay’s lab that is highly resistant to SN-
38 treatment. This cell line, termed HT-29S, has been developed by sequentially increasing cell line 
exposures to the drug in the culture media. Briefly, the cell line was developed starting with the HT-29 cells 
in the culture media, and gradually increasing the SN-38 concentration in 6 steps from 0.1 nM in the first 
week to 100nM after 3 weeks [51]. 
The HT-29 and the HT-29S resistant cells were cultured in Nunc T25 culture flasks (Thermo Scientific 
Fisher) at 37°C in a humidified incubator with 5% CO2. Hyclone DMEM containing 4mM L-glutamine and 
4500 mg/L L-glucose, 1mM sodium pyruvate, and 10% FBS was used as well. In addition, HT-29S cell 
cultures had 30nM SN-38 (Sigma Aldrich) added to the growth media. Cultures that were reaching 
confluency were passaged after suspension by several minutes’ exposure to 1mL TrypLE Express (Life 
Technologies) at 37°C. Subsequently, 10-15% of the cells were seeded in a new culture flask with fresh 
media. 
Cell samples were prepared for the iTRAQ experiment by Ms. Julia Fux in Dr. Blay’s lab. The HT-29 
and HT-29S cells were grown to 80-90 % confluency in T75 culture flasks. Then, cells were suspended 
using 0.25% Trypsin-EDTA (Gibco) and transferred into 15 ml tubes. After centrifugation at 300x g at 4°C, 
the media was removed and the remaining cell pellets were washed with cold PBS to completely remove 
the media and trypsin. The washing step was repeated for 5 times and cells were stored at -80°C. 
4.2.2 Protein sample preparation and iTRAQ labeling 
The whole cell proteome extraction was done using the stored frozen cell pellets. Cells were quickly thawed 
on ice and 700 μl of the lysis buffer was added to the samples in microtubes. The lysis buffer was freshly 
prepared using 100mM HEPES at pH 7.5, 1% Triton X-100, 100mM dithiothreitol (DTT), and 5 μl of the 
protease inhibitor cocktail from Sigma Aldrich (P8340). The samples were incubated on ice at 
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approximately 4°C for 30min. Once the lysis buffer starts to disrupt the cells, proteases may degrade the 
proteins, and the protease inhibitor cocktail prevents this unwanted process. To ensure that proteins are not 
aggregated and extra disulfide bonds are not created, it is necessary to use a reducing agent like DTT or 
TCEP. The reducing agent cleaves disulfide bonds and prevents formation of protein aggregates. The lysate 
samples were centrifuged at 10,000x g and the supernatant was extracted leaving the cell debris to discard. 
The protein concentration was measured at this step using Bio-Rad microplate protein assay [91] (Bio-
Rad Laboratories Ltd., Mississauga, Canada). Following the Bradford method, a set of standard protein 
samples was prepared using bovine serum albumin (BSA) (Sigma-Aldrich, ON, Canada). Six standard BSA 
samples containing 0, 0.2, 0.4, 0.6, 0.8, and 1 mg/ml of protein were used to create the linear standard curve. 
A Multiskan UV microplate spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA) was 
used to read the corresponding absorbance of the samples at 595nm. 
According to the protein concentration of each sample, a volume equivalent of 1mg protein was separated 
from the cell lysates. Next, the protein lysate samples were precipitated using the Calbiochem ProteoExtract 
kit from EMD Millipore (Cat# 539180). The kit provided the precipitation agent and the wash solution that 
were prepared following the manufacturer’s protocol and stored at -20°C prior to the process. Samples 
consisting of 1 mg of the protein lysate were precipitated using 4 times volume of the precipitation agent 
and incubated at -20°C for a minimum of 1 hour. After centrifugation at 10,000x g speed in 4°C protein 
pellets were collected and the supernatant was discarded. Then, protein pellets were washed by adding 500 
μl of wash solution (at -20°C) and quickly disrupting the pellet. The wash step was repeated for two times 
and without disrupting the pellets the wash solution was discarded. The protein samples were re-suspended 
in UA buffer, containing 8M Urea and 100mM HEPES buffer at pH 8.6. The protein concentration of each 
sample was measured by Bradford microplate assay and 250 µg of completely solubilized proteins from 
each sample was used in the next step. 
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Filter-aided protein sample preparation was used for protein purification and digestion [93]. Amicon 
Ultra centrifugal filters (UFC500324, Merck Millipore, MA, USA) with relative molecular mass cut-off of 
3k were used in this experiment following the manufacturer’s protocol. Protein samples were loaded on the 
wetted filters in the chaotropic UA buffer, keeping the proteins completely solubilized. Then, proteins were 
alkylated to block cysteines by adding 50 mM iodoacetamide (IAM) to the UA buffer. The buffer was 
changed to 0.5 M triethylammonium bicarbonate pH 8.5 (TEAB) prior to trypsin digestion. Lyophilized 
trypsin was used with an approximate ratio of 1:50 trypsin to protein, with 20 μg trypsin used for each 
sample. Samples were stored at 37°C in a bead bath for approximately 8 hours overnight. The digested 
samples were dried in a Thermo Scientific Savant Speed Vac vacuum centrifuge to deactivate trypsin and 
re-suspended in 30 μl of TEAB buffer. Concentration of the digested proteins was estimated at this stage 
using the A280 method [93] on a NanoDrop™ 2000 spectrophotometer (Thermo Fisher Scientific, 
Wilmington, DE, USA). 
Following iTRAQ manufacturer’s protocol, equal amounts of 8 peptide samples were labeled using the 
eight isotopic labeling reagents in the kit. To assure efficiency of the labeling process, pH was tested by 
Hydrion pH papers and adjusted with TEAB buffer to stay between 7.5 and 8.5. After one hour incubation 
at room temperature, labeled samples were mixed into one microtube and evaporated using a Speed Vac® 
centrifuge from Savant (Thermo Fisher Scientific, Waltham, MA, USA). Then, the sample was resuspended 
in a buffer, containing 70% acetonitrile and 0.1% formic acid. Then the sample was sent for mass 
spectrometry analysis at the mass spectrometry facility of SPARC BioCentre at the SickKids hospital, 
Toronto, as described in section 2.2.4. 
  
  
56 
4.3 Results 
4.3.1 Protein identification and quantitation by PEAKS 
The iTRAQ mass spectrometry data was consisted of 79,278 MS/MS scans, and after filtering a total of 
19,544 peptide sequences were identified by the de novo sequencing analysis in PEAKS. The average local 
confidence scores for de novo sequenced peptides are shown in figure 4.1. The database search identifies 
peptide sequences that match the spectrum using de novo analysis, and the identified proteins containing 
these peptides will be reported in groups of closely similar sequences. A PEAKS database search through 
the NCBI non-redundant (nr) human protein sequences could match 11,798 peptide sequences with a 
minimum confidence score of 15. A total of 9,168 proteins were identified within 1,665 protein groups, and 
the top protein within a group with the highest score and highest number of peptides identified is reported 
as a unique protein and is used in the expression analysis. Figure 4.2 shows the PSM (peptide spectrum 
match) score distribution and figure 4.3 shows the FDR curve for the PSMs. 
Quantitation within PEAKS 7.5 identified 1,665 groups of proteins with at least one unique peptide hit 
identified for each of the 1665 proteins. Expression data of these 1,665 unique proteins were tested and 370 
proteins had statistically significant differences in expression level between the HT-29 and the HT-29S 
resistant cells. Based on the Benjamini-Hochberg method for multiple hypotheses testing correction with q 
as 0.05, the p-value threshold was set to 0.016. 
4.3.2 Differential expression analysis of HT-29 vs. HT-29S proteome 
Differential expression analysis of the high-throughput mass spectrometry data provides a near-
comprehensive look at the proteome of the HT-29 cells and the resistant cells. Relative abundances of 
identified proteins in the HT-29 and HT-29S samples were compared and plotted as statistical significance 
vs. fold change (Figure 4.4). The lists of genes that are significantly up- or down-regulated respectively in 
the resistant cells are presented in Tables 4.1 and 4.2. 
  
57 
The most significantly up-regulated gene is PAGE4 (cancer/testis antigen prostate-associated family 
member 4) and a member of GAGE family (Table 4.1). The cancer/testis antigens (CTAs) are 
heterogeneous proteins expressed in the normal tissue of testis. A variety of tumors and some reproductive 
tissues express GAGE genes. Based on several studies on the function of PAGE4, it is an intrinsically 
disordered protein (IDP) and highly expressed in fetal prostate and benign or malignant prostate disease 
cells as well as cancer cells in other reproductive tissues [96]. Importantly, PAGE4 is also a stromal marker 
that may be associated with an epithelial to mesenchymal transition (EMT) [97]. 
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Figure 4.1: Peptide confidence score distribution vs. mass error in ppm. The target-decoy method is 
used in PEAKS to estimate the FDR, decoy hits shown in brown and target hits in blue. For high 
confidence, we expect to have few decoys with high scores and a large number of search results. 
  
59 
 
 
 
 
 
Figure 4.2: The distribution of the identified peptide scores for the peptide spectrum matches 
(PSMs) shown in Figure 4.1. The majority of correctly identified target peptide residues have high 
local confidence scores, whereas the majority of decoy peptides have low scores. The dashed line is 
represents a default threshold. A threshold of 20 was used for further analysis to reduce the number of 
false positives.  
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Figure 4.3: The false discovery rate curve for peptide spectrum matches (PSM) used in protein 
identifications. The curve represents the FDR associated to the number of peptide-spectrum matches 
that are in the database search result. The vertical dashed line is indicating the score threshold based 
on the selected score threshold for the FDR lower than 5%. 
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Figure 4.4: Volcano plot log2(FC) vs. –log(p-value), the red dots are labeled and representing the 
significantly regulated proteins using an FDR threshold of q = 0.05 and | logFC | ≥ 1.0. 
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Table 4.1: List of genes and protein ids that are significantly up-regulated, passing an FDR 
threshold of q < 0.05 and with greater than 2-fold change in expression ( | logFC | ≥ 1 )  in HT-29S 
cells. The full list of proteins passing FDR q < 0.05 (p < 0.016) is given in Appendix A. 
Gene 
Symbol 
logFC P-value Genbank GI Protein 
PAGE4 2.3 1.2E-03 5901986 
Prostate associated gene, P antigen 
family member 4 
UCHL1 1.7 2.2E-05 136681 
Ubiquitin carboxyl-terminal hydrolase 
isozyme L1 
FABP5 1.3 2.8E-03 4557581 fatty acid-binding protein, epidermal 
IGF2B1 1.2 3.5E-04 56237027 
insulin-like growth factor 2 mRNA-
binding protein 1 
FABP7 1.2 1.1E-03 4557585 fatty acid-binding protein, brain 
ARID3A 1.2 3.3E-03 56799575 
AT-rich interaction domain 3A, 
DRIL1 
AKAP2 1.1 3.5E-07 310772255 A-kinase anchor protein 2 
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Table 4.2: List of genes/protein Ids that were down-regulated in HT-29S cell line (passing FDR 
threshold of q = 0.05) and with greater than 2-fold change in expression (| logFC | ≥ 1)   
Gene Symbol logFC P-value Genbank GI Protein 
CA2 -1.8 1.9E-04 245850 S-100P=Ca(2+)-binding protein 
DRAP1 
-1.8 2.2E-03 18426973 dr1-associated corepressor 
MSN -1.8 1.1E-04 4505257 Moesin 
CRIP1 -1.6 4.0E-04 4503047 Cysteine-rich protein 1 
LYVE1 -1.4 1.3E-04 40549451 
Lymphatic vessel endothelial 
hyaluronic acid receptor 1 precursor 
KRT18 -1.4 1.1E-03 30311 Cytokeratin 18  
KRT20 -1.4 5.9E-03 27894337 Keratin  type I cytoskeletal 20 
PFN2 -1.3 4.1E-07 16753215 Profilin-2 isoform a 
BCAS1 -1.3 3.5E-04 530418484 
Breast carcinoma-amplified sequence 1 isoform 
X6 
HSPA1A -1.3 2.9E-04 194388088 heat shock 70 kDa protein 
CAPG -1.1 9.9E-05 1002819390 macrophage-capping protein isoform 3 
STARD10 -1.1 1.2E-04 119595276 START domain containing 10 isoform CRA_c 
EPPK1 -1.0 2.7E-03 119602582 epiplakin 1 
SERPINA1 -1.0 1.1E-04 6855601 PRO0684 
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IDPs can be involved in the cellular processes where binding with high specificity and low affinity is 
important, for example they are involved in signaling and regulating transcription processes. There is often 
an association between overexpression of IDPs and human diseases including cancer. So, IDPs such as tau 
protein, p53, and BRCA1 are possible targets for drugs that modulate protein-protein interactions [96]. 
Zeng et al. explored the DNA binding preferences of PAGE4 and revealed that it binds to GC-rich 
sequences and possibly PAGE4 is functioning as a transcription factor or a sequence-specific DNA-binding 
protein. This protein is involved in stress responses, preventing DNA damage, inhibition of apoptosis 
caused by stresses, and suppressing reactive oxygen species [96, 98]. 
In a study by Iavarone et al., PAGE4 was identified as potentially down-regulating the transcription of 
lipoprotein lipase, suggesting a transcription factor function for this gene [99]. High expression levels of 
some CTAs including PAGE4 have shown associations with drug-resistant cancer cells [96, 100]. Cells 
over-expressing PAGE4 had a significant increase in cell viability and its down-regulation had shown to 
decrease cell survival [96].  
PAGE4 suppression resulted in significant increase of protein p21 and phospho-p53, which suggests that 
PAGE4 is playing a role in protecting cells against stress and apoptosis. Protein p21 inhibits cyclin kinase 
activities by binding to the CDK2 and CDK4 complexes, and regulates progression of the cell cycle at G1. 
The tumor suppressor protein p53 also controls p21 expression and is involved in p53-dependent cell cycle 
arrest at G1 phase in reaction to stresses [96, 101]. 
UCHL1 gene is coding an enzyme that modifies ubiquitins at specific sites. According to pathway 
networks, regulation of Uchl1 is related to Chks in checkpoint regulation pathway that is related to DNA 
repair pathways as well as the G2-M phase transition. 
Insulin-like growth factor binding protein (IGF2B1) regulates several transcripts by binding to mRNAs, 
such as beta-actin (ACTB) mRNA translation that is essential for determining cell polarity and cell 
migration. IGF2 has interactions with PTGS2 mRNA and stabilizes this transcript during colonic wound 
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healing. It can also bind to and stabilize the CD44 transcript, thereby promoting cell adhesion and 
invasiveness in cancer cells [102, 103]. Up-regulation of IGF2 is associated with faster tumor progression 
in various cancers [104]. 
GFBPs can effect adhesion and migration of cells and enhance the action of IGFs [105]. IGFBP-1 
contains a recognition sequence for integrin receptors in its primary structure, which allows it to specifically 
bind the fibronectin receptor, α5β1 integrin [106]. 
Fatty acid binding protein (FABP) has an affinity for lipid ligands and is known for numerous biological 
functions such as modulation of cell growth and proliferation. Also, in a study on drug-resistant pancreatic 
adenocarcinoma cells FABP, cofilin, and stratifin were significantly overexpressed, suggesting that 
overexpression of FABP proteins could be possibly involved in removal of cytotoxic drugs [107]. Arid3A 
is a transcription factor involved in controlling the progression of cell cycle by RB1/E2F1 pathway. 
Although ARID3A has very low expression level in the colon and stomach tissue, it is strongly over-
expressed in stomach tumors and is suggested as a cancer marker [108]. Increased expression of actinin-4 
induces cell migration and motility [109]. 
The protein coding BSG, also known as CD147, is also significantly up-regulated, although with a lower 
fold change of log FC = 0.52 (see Appendix B) in the resistant cells. CD147 regulates synthesis of 
hyaluronan (HA) and interacts with the HA receptors, CD44, and LYVE-1 [110]. This protein is also 
involved in production of matrix metalloproteinases (MMPs) by stimulating adjacent fibroblasts. MMPs 
are known as targets in cancer therapy and are linked to chemoresistant cancer cells through regulation of 
autophagy and apoptosis pathways [111].  
The main function of cytokeratins is in stabilizing the cells and other possible functions as well. Among 
the intermediate filament gene family, cytokeratins are the most complex genes with acidic and basic types 
based on their charge, with the KRT9-20 being in the acidic subdivision and KRT1-8 in the basic type 
[112]. Cytokeratin genes are positive and highly investigated markers in colorectal cancer. Cytokeratin 20 
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(KRT20) is found to be expressed in 95% of CRC primary and metastatic tumors and it is a marker for 
detection of circulating CRC cells, because normally epithelial cells that express KRT20 are not in 
circulation [113]. A statistically significant trend has been detected in KRT20 positive patients with 
increasing stages of disease [113]. The expression profile of KRT20 is a factor in selecting treatment options 
for CRC patients, and Kust et al. suggested that more aggressive treatments could be used for patients with 
positive KRT20 after operation. KRT18-20 and KRT80 were observed in the protein data significantly 
down-regulated in the resistant cells, as well as KRT7 which is up-regulated with a fold-change of 0.67. 
Breast carcinoma amplified sequence 1 (BCAS1) is over-expressed in most breast cancer cells, but down-
regulated in colorectal tumors. It is also expressed in many organs like brain, colon and prostate. In our 
drug-resistant HT-29S cell line, BCAS1 had a significant down-regulation.  
Another protein that has significant decrease in HT-29S cells is profilin-2, which is known that is 
involved in several pathways related to regulation of actin cytoskeleton and cytoskeletal remodeling. It is a 
ubiquitous actin binding protein in the profilin family that has a crucial role in cellular motility, along with 
several other genes that are known as actin binding components and were down-regulated in the resistant 
cell line (Table 4.3). Profilin-2 reacts to extracellular signals by binding to actin and regulating actin 
polymerization and structure of the cytoskeleton. The polymerization of actin increases when the level of 
profilin-2 is in low concentrations. It has been studied that how regulation of the PFN2 gene can affect the 
migration, invasion, and stemness features of HT-29 cells [114]. Profilin-2 regulates the expression of E-
cadherin and snail that are EMT markers as well as the expression of some stem cell marker proteins, 
CD133, SOX2, and β-catenin. Kim et al. 2015 showed that knockdown of profilin-2 increased expression 
of E-cadherin and suppressed the expression of snail [114]. 
In the iTRAQ analysis of the HT-29S cell line, expression level of CKB was significantly decreased with 
a fold-change difference of 1.0 (see Appendix B). Creatine kinases (CK) are involved in reversible catalysis 
of the transfer of phosphate between ATP and creatine phosphate. Creatine kinase brain (CKB) is a 
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cytosolic isoform of creatine kinase family of enzymes. CKB is mainly expressed in the brain and it is 
overexpressed in many cancer cells, but in colon cancer cells it is may be downregulated. By subcellular 
fractionation the overall levels of CKB showed a decrease in colon cancers, whereas nuclear matrix proteins 
from normal and colon cancer samples had overexpressed CKB. CKB has shown to be expressed localized 
in the nuclear matrix. In a study by Mooney et al. (2011), which looked into the role of CKB in 
tumorigenesis in colon cancer cells, downregulation of CKB appears to promote epithelial-to-mesenchymal 
transition (EMT) in these cells [115]. Along with the qPCR analysis they found that the protein and mRNA 
levels had significantly decreased in colon cancer. 
Knowing that CKB may be downregulated in colon cancer cells and this enzyme is involved in energy 
transduction, cells are likely under metabolic stress. Lower expression level of CKB in the resistant cells 
could be a sign of more aggressive cancer cells (that is putting cells under stress). 
Also, previous results have indicated that with downregulation of CKB the expression levels of PAGE4 
and SNAIL were increased [115]. Consistent with this study, protein expression level of PAGE4 in the 
resistant cell line HT-29S significantly increased by 2.26 fold within the current study as well. 
Moesin (MSN) functions as cross-linker for plasma membranes and actin-based cytoskeletons. Moesin 
is important for cell-cell signaling and movement. It was shown in studies on human lymphoid cells that 
moesin could have a role in regulating cell proliferation, migration and cell adhesion, as well as 
immunologic synapse formation [116]. 
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4.4. Functional analysis of differentially regulated proteins 
Functional analysis of pathways was done with DAVID [84], using the list of genes (Appendix B) that had 
significant differential expression of proteins in the high-producing cells independent of fold change. Using 
DAVID analytical tool [84], enriched gene ontology (GO) terms and KEGG pathways and identified and 
their biological annotations are used to classify key functions and pathways that could be linked to drug 
resistance in the treated cells. The tables reported below include enriched biological processes, molecular 
functions, and cellular components, the enriched pathways from KEGG database search, and the enriched 
transcription factor binding cites. 
In this section, only the significantly enriched results from functional analysis using DAVID are shown 
and discussed. Two sets were prepared; a gene set of the significantly down-regulated proteins and a gene 
set of significantly up-regulated proteins were uploaded on DAVID. Human genome (Homo sapiens) was 
selected as the species and gene population background at the gene list manager section. 
Table 4.3 contains the significantly enriched GO terms from the down-regulated gene set, with the genes 
related to the top annotation cluster shown in table 4.4. The cluster with the highest enrichment score are 
functions related to cell-cell adhesion and among other highly enriched terms, features are common with 
the aggressive types of cancer cells and cancer stem cells. Table 4.5 shows the significantly enriched GO 
terms from the up-regulated gene set, and Table 4.6 shows the gene members of the corresponding GO 
terms. Lastly, Table 4.7 shows the enriched KEGG pathways from the up- and down- regulated gene sets. 
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Table 4.3: Significantly enriched functional annotation clusters observed from the down-regulated 
genes in the resistant cell line  
Cluster 
Enrichment 
Score 
Enriched Terms 
GO terms 
IDs 
# of Genes 
Involved 
FDR 
1 19.86 
Cadherin binding involved in cell-cell 
adhesion 
GO:0098641 31 5.0E-18 
cell-cell adherens junction GO:0005913 31 1.8E-17 
cell-cell adhesion GO:0098609 29 8.6E-17 
2 7.37 
Actin-binding UniProt 
Keyword 
22 1.1E-10 
Actin filament binding GO:0051015 10 1.7E-02 
Actin cytoskeleton GO:0015629 11 9.6E-02 
3 5.73 
Ribosomal protein UniProt 
Keyword 
14 2.0E-05 
Translational initiation GO:0006413 13 3.6E-05 
SRP-dependent cotranslational protein 
targeting to membrane 
GO:0006614 11 8.8E-05 
Ribonucleoprotein UniProt 
Keyword 
16 1.2E-04 
Ribosome GO:0005840 13 1.5E-04 
Viral transcription GO:0019083 11 4.7E-04 
nuclear-transcribed mRNA catabolic 
process, nonsense-mediated decay 
GO:0000184 11 8.2E-04 
Structural constituent of ribosome GO:0003735 14 1.1E-03 
Ribosome Pathway hsa 03010 12 3.3E-03 
rRNA processing GO:0006364 13 4.6E-03 
Translation GO:0006412 14 4.6E-03 
4 3.12 prefoldin complex GO:0016272 4 4.4E-02 
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Table 4.4: The top annotation cluster of differentially down-regulated proteins and the group of genes 
related to each term. 
Category Term Genes 
Fold 
Enrichment 
FDR 
Molecular 
Function 
Cadherin binding 
involved in cell-cell 
adhesion 
GO:0098641 
LDHA, LIMA1, PDLIM5, HSPA1A, SFN, 
TAGLN2, EFHD2, PAK2, RPL6, RANBP1, 
LRRFIP1, EHD1, PLEC, DBNL, LAD1, ANXA1, 
SLC9A3R2, VASP, TNKS1BP1, CORO1B, 
KRT18, ITGA6, CGN, LASP1, CAPG, TMOD3, 
EPS8L2, TJP2, DBN1, EPS8L1, SPTAN1 
9.91 5.0E-18 
Cellular 
Component 
Cell-cell adherens 
junction 
GO:0005913 
LDHA, LIMA1, PDLIM5, HSPA1A, SFN, 
TAGLN2, EFHD2, PAK2, RPL6, RANBP1, 
LRRFIP1, EHD1, PLEC, DBNL, LAD1, ANXA1, 
SLC9A3R2, VASP, TNKS1BP1, CORO1B, 
KRT18, ITGA6, CGN, LASP1, CAPG, TMOD3, 
EPS8L2, TJP2, DBN1, EPS8L1, SPTAN1 
9.51 1.8E-17 
Biological 
Process 
Cell-cell adhesion  
GO:0098609 
LDHA, LIMA1, PDLIM5, HSPA1A, SFN, 
TAGLN2, EFHD2, PAK2, RPL6, RANBP1, 
LRRFIP1, EHD1, PLEC, DBNL, LAD1, 
SLC9A3R2, VASP, TNKS1BP1, CORO1B, 
KRT18, CGN, LASP1, CAPG, TMOD3, 
EPS8L2, TJP2, DBN1, EPS8L1, SPTAN1 
10.10 8.6E-17 
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Table 4.5: The most enriched gene ontology terms from the list of differentially up-regulated proteins 
with the group of genes related to each term. 
Category Term 
GO terms 
IDs 
# of Genes 
Involved 
Fold 
Enrichment 
FDR 
Molecular 
Function 
Poly(A) RNA binding GO:0044822 41 3.52 3.8E-09 
Protein binding GO:0005515 130 1.44 1.2E-06 
Biological 
Process 
Cell proliferation  GO:0008283 15 4.17 0.02 
Cellular 
Component 
Extracellular exosome GO:0070062 73 2.78 1.9E-14 
Cytosol GO:0005829 73 2.36 1.8E-10 
Cytoplasm GO:0005737 88 1.81 4.1E-07 
Nucleoplasm GO:0005654 58 2.23 2.3E-06 
Myelin sheath GO:0043209 12 8.46 2.3E-04 
Mitochondrial matrix GO:0005759 15 4.92 0.003 
Cell-cell adherens junction GO:0005913 14 4.65 0.01 
Spliceosomal complex GO:0005681 8 9.12 0.04 
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Table 4.6: The group of genes related to the most enriched terms listed in table 4.5 
Category Term Genes 
Fold 
Enrichment 
FDR 
Molecular 
Function 
Poly(A) RNA 
binding 
GO:0044822 
XRCC5, PUS1, FKBP4, SNRPD1, SNRPD2, 
IGF2BP1, CCT3, SERPINH1, SRRT, SAFB, 
C1ORF52, TPT1, QKI, HSPE1, UBAP2L, 
CCAR2, RBM26, GNL3, ENO1, CLNS1A, 
ALDH6A1, EEF1A1, NOC4L, LGALS3, 
TRIM28, FSCN1, HLA-A, PRPF3, HNRNPA1, 
PRPF6, EIF4B, APEH, RBPMS, CCT4, ILF2, 
VCP, THRAP3, MAPRE1, FARSA, POP7, DUT 
3.52 3.8E-09 
Biological 
Process 
Cell 
proliferation 
GO:0008283 
XRCC5, BCAT1, NASP, FSCN1, UCHL1, SRA1, 
SRRT, KIF2C, PPP1R8, TACSTD2, RAP1B, 
YAP1, MAPRE1, LRP2, GNL3 
4.17 0.02 
Cellular 
Component 
Extracellular 
exosome 
GO:0070062 
ALAD, ATP5B, PITPNA, UCHL1, SNRPD2, 
CCT3, CD2AP, PDHB, VCL, MTHFD1, TPT1, 
IMPDH2, ALDH6A1, BSG, PTPRF, ERP29, 
HLA-A, PROSC, CTSV, SPAG9, NPC2, CLIC3, 
PRDX6, CLIC4, TACSTD2, CFL2, PDCD6IP, 
CA2, LCP1, UGP2, FKBP4, SNX2, DAG1, 
PPT1, SNX3, ATP6V1B2, UBAC1, ACAT2, 
SERPINH1, ACP1, TPM4, PFAS, ATIC, KRT7, 
HSPE1, LAMB1, ENO1, EEF1A1, PARD6B, 
LGALS3, VTA1, FSCN1, GARS, SOD1, 
HNRNPA1, ANXA3, ERP44, APEH, PSMC6, 
CCT5, CCT4, VCP, HEBP1, THRAP3, FABP3, 
PHGDH, QPRT, RAP1B, LRP2, PHPT1, 
AHSA1, FABP5, DUT 
2.78 1.9E-14 
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Table 4.7: Enriched KEGG pathways in the candidate genes list.  
Gene list 
KEGG 
pathway 
Genes 
Benjamini 
Adjusted p-value 
Up-regulated 
genes 
Biosynthesis 
of antibiotics 
BCAT1, PGM3, ATIC, ARG2, PHGDH, HMGCS1, 
ACAT2, PCCB, UGP2, PFAS, PDHB, ENO1 
0.01 
Down-regulated 
genes 
Ribosome RPL19, RPS17, MRPL14, RPL13A, RPL13, RPL6, 
RPL21, RPS15, RPL11, RPL12, RPS4X, RPS23 
5.0E-04 
 
 
4.5 Discussion  
Cancer stem cells have been found in primary and malignant CRC tumors and hypothesized to be 
resistant to chemotherapy treatments [117]. In addition, stem cell markers are enriched in recurrent CRCs 
after chemotherapies. There are experimental evidence that carcinoma associated fibroblasts (CAFs) play 
significant roles in affecting the sensitivity to a several chemotherapy agents [118]. Also it has been shown 
that targeting the fibroblasts can considerably decrease the chemoresistance [118]. These carcinoma 
associated fibroblasts increase chemo-resistance through CAF-derived exosomes. 
Extracellular exosome is the top enriched cellular component, and exosomes are evidently known as a 
mark of metastatic cells. Their involvement in the expelling of drugs by carrying ABC transporters supports 
the exosomes function in drug resistance [119]. A number of Rab family proteins are among the key 
regulators of exosome secretion [119]. 
The only significantly enriched KEGG pathway using the list of up-regulated gene is the biosynthesis of 
antibiotics and for the list of down-regulated genes the ribosome pathway is enriched (Table 4.7). This 
could show the significant changes in the drug efflux in cells that may have resulted in the resistance. 
Ribosomal proteins are linked to proliferation, progression, and metastasis of colorectal cancer cells [120]. 
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Several proteins with significant changes in the resistant cells, such as PAGE4 and cytokeratins have 
been known for malignant types of cancer, cancer stem cells, or links to EMT in cancer cells. Also, the cells 
skeletal features, adhesion and migration showed significant differences in the drug-resistant state. 
Exploring the proteome allowed us to recognize the mechanisms and pathways that were differentially 
regulated. Proteins that are related to cell-cell adhesion, actin binding, and ribosomal pathway have 
decreased expression levels (Table 4.3). Whereas, proteins related to the cell proliferation processes and 
biosynthesis of antibiotics pathway are increased in the resistant cell line (Table 4.5). While cells are more 
aggressively growing, it can be expected to have a decrease in RNA processes, protein folding, translation, 
and ribosome pathway.  
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Chapter 5 
Conclusions  
5.1 Quantitative proteomic analysis of inducible CHO cells 
In this thesis, a quantitative proteomic analysis using iTRAQ technique was performed to compare the 
inducible CHO cells with cumate treatment while producing high amounts of the heavy chain antibody, 
EG2-hFc1. The inducible CHO cell line with the CR5 promoter and cumate gene switch were able to 
produce almost six times the amount of mAb product in presence of cumate. The successful iTRAQ 
labelling and mass spectrometry analysis allowed us to quantify the expression level of 3,410 proteins. A 
list of 1,616 unique proteins with a valid expression levels was used in differential expression analysis, 
which identified 82 proteins with a p-value lower than 0.05. After the corrections for multiple hypothesis 
testing an FDR threshold of 0.25 would detect 8 proteins that have significantly regulated in addition to the 
mAb product. Three proteins had an increase in the expression levels, and five of them had a decrease, but 
none of the significant changes were large. 
The differentially regulated proteins were precursor metabolites, involved in metabolic pathways and 
energy uptake. Biological processes and functions of the candidate genes included translation, mRNA 
splicing, protein folding and protein modifications. However, these proteins did not show large changes in 
the cumate induced cells and all of the proteins had a log-fold change lower than 0.3 and greater than -0.4. 
Therefore it is likely that the cumate induction system is not causing larger metabolic shifts or stress 
responses within the cell. However, further investigation could help in understanding the system better, for 
example by testing the metabolites during the cell culture and mAb production at different scales, testing 
the cells and metabolites at several time intervals would also add more information about the induced cells. 
Overall, the cells did not show to have a strong stress response in producing high levels of mAb, and 
small changes in the metabolism and translational pathways are identified. The two conditions did not have 
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any large significant difference in the proteome that can show this inducible expression system has 
successfully generated a stable cell line with higher production capacity. 
My work in this thesis explores the changes in quantitative protein expression levels of the inducible 
CHO cell line associated with increased EG2-hFc1 production. The outcome and results can be a reference 
for any future studies performed using this cell line or the inducible expression system. Based on this 
proteomic study, the increase in production of this mAb did not significantly change the cells main 
metabolisms to induce stress responses. Other bioinformatics analysis of cells with this inducible system, 
or with various levels of production, or with another mAb product would provide more insights into the 
cellular changes that may be changing with the increase in protein secretion levels. Additionally, proteomic 
and metabolomics study of the cells at different time frames and different scales of production will provide 
extensive information on the changes related to growth and production process. In addition to further 
experimental studies that could help understanding the cells process, more analysis on the published data 
such as genes with unknown functions could be beneficial.  
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5.2 Quantitative proteomic analysis of drug-resistant HT-29 cell line 
In the second part of the thesis, a quantitative proteomic analysis was performed for comparison of the HT-
29 and HT-29S cell lines. The HT-29S cells are developed to become resistant to SN-38 treatment, and this 
analysis would help us in understanding the details of the resistance mechanism in the CRC cells. The cell 
line was generated with an increasing exposure to the drug treatment during the culture. 
Using the iTRAQ labeling technique, peptide samples from 4 replicates of the HT-29 cell line and 4 
replicates of the resistant HT-29S cell line were labeled and prepared for MS analysis. Then we were able 
to test the expression of 1,665 unique proteins for any differences between the two groups and 370 proteins 
were identified with statistically significant differences and a fold-change greater than 0.3. 
Within the up-regulated gene list biosynthesis of antibiotics pathway was significantly enriched with 12 
related genes, and the ribosome pathway was identified as a significantly enriched pathway among the 
down-regulated genes list (Table 4.7). Since the identification of several ribosomal proteins that had been 
down-regulated in the resistant cell line, regulation of ribosomal proteins is associated with the progression 
of CRC. The protein, PAGE4 is identified as the most significantly up-regulated protein in the resistant 
cells, this protein was previously known for its functions in the prostate cancer cells, but this is the first 
identification in HT-29 cells. These results could be further investigated by comparing to information from 
patients’ tumor studies. 
Transcription factors are known to have a role in regulating a number of cancer cell processes, for 
example the EMT process, but this method may be weak in including and quantifying some types of 
proteins, such as the transcription factors. A future study on the proteome or transcriptome of the resistant 
cells could be focused on considering transcription factors. Further analysis on the proteins with unknown 
functions or the network analysis could be done on the published data, as well as integrating information 
from external studies. 
  
  
78 
References 
1. Strebhardt, K. and A. Ullrich, Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev 
Cancer, 2008. 8(6): p. 473-480. 
2. Kohler, G. and C. Milstein, Continuous Cultures of Fused Cells Secreting Antibody of Predefined 
Specificity. Nature, 1975. 256(5517): p. 495-497. 
3. Weiner, G.J., Building better monoclonal antibody-based therapeutics. Nat Rev Cancer, 2015. 
15(6): p. 361-370. 
4. Liu, J.K., The history of monoclonal antibody development - Progress, remaining challenges and 
future innovations. Ann Med Surg (Lond), 2014. 3(4): p. 113-6. 
5. EvaluatePharma, World Preview 2014, Outlook to 2020. Evaluate, Ltd.: Boston, MA, 2014, 2014. 
6. Ecker, D.M., S.D. Jones, and H.L. Levine, The therapeutic monoclonal antibody market. Mabs, 
2015. 7(1): p. 9-14. 
7. Kim, J.Y., Y.G. Kim, and G.M. Lee, CHO cells in biotechnology for production of recombinant 
proteins: current state and further potential. Appl Microbiol Biot, 2012. 93(3): p. 917-930. 
8. Xu, X., et al., The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line. Nat 
Biotechnol, 2011. 29(8): p. 735-41. 
9. Demain, A.L. and P. Vaishnav, Production of recombinant proteins by microbes and higher 
organisms. Biotechnol Adv, 2009. 27(3): p. 297-306. 
10. Ko, K., Expression of recombinant vaccines and antibodies in plants. Monoclon Antib 
Immunodiagn Immunother, 2014. 33(3): p. 192-8. 
11. Chiu, M.L. and G.L. Gilliland, Engineering antibody therapeutics. Curr Opin Struct Biol, 2016. 
38: p. 163-73. 
12. Sola, R.J. and K. Griebenow, Glycosylation of Therapeutic Proteins An Effective Strategy to 
Optimize Efficacy. Biodrugs, 2010. 24(1): p. 9-21. 
13. Datta, P., R.J. Linhardt, and S.T. Sharfstein, An 'omics approach towards CHO cell engineering. 
Biotechnol Bioeng, 2013. 110(5): p. 1255-1271. 
14. Werner, R.G., et al., Appropriate mammalian expression systems for biopharmaceuticals. 
Arzneimittel-Forsch, 1998. 48(8): p. 870-880. 
  
79 
15. Jayapal, K.R., et al., Recombinant protein therapeutics from CHO cells - 20 years and counting. 
Chem Eng Prog, 2007. 103(10): p. 40-47. 
16. Tjio, J.H. and T.T. Puck, Genetics of somatic mammalian cells. II. Chromosomal constitution of 
cells in tissue culture. J Exp Med, 1958. 108(2): p. 259-68. 
17. Shire, S.J., Formulation and manufacturability of biologics. Curr Opin Biotech, 2009. 20(6): p. 
708-714. 
18. Rita Costa, A., et al., Guidelines to cell engineering for monoclonal antibody production. Eur J 
Pharm Biopharm, 2010. 74(2): p. 127-38. 
19. Wuest, D.M., S.W. Harcum, and K.H. Lee, Genomics in mammalian cell culture bioprocessing. 
Biotechnol Adv, 2012. 30(3): p. 629-38. 
20. Cockett, M.I., C.R. Bebbington, and G.T. Yarranton, High level expression of tissue inhibitor of 
metalloproteinases in Chinese hamster ovary cells using glutamine synthetase gene amplification. 
Biotechnology (N Y), 1990. 8(7): p. 662-7. 
21. Alt, F.W., et al., Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant 
variants of cultured murine cells. J Biol Chem, 1978. 253(5): p. 1357-70. 
22. Lee, J.S., et al., Site-specific integration in CHO cells mediated by CRISPR/Cas9 and homology-
directed DNA repair pathway. Sci Rep-UK, 2015. 5. 
23. Malphettes, L., et al., Highly Efficient Deletion of FUT8 in CHO Cell Lines Using Zinc-Finger 
Nucleases Yields Cells That Produce Completely Nonfucosylated Antibodies. Biotechnol Bioeng, 
2010. 106(5): p. 774-783. 
24. Khan, K.H., Gene expression in Mammalian cells and its applications. Adv Pharm Bull, 2013. 
3(2): p. 257-63. 
25. Broussau, S., et al., Inducible packaging cells for large-scale production of lentiviral vectors in 
serum-free suspension culture. Mol Ther, 2008. 16(3): p. 500-7. 
26. Gaillet, B., et al., High-level recombinant protein production in CHO cells using lentiviral vectors 
and the cumate gene-switch. Biotechnol Bioeng, 2010. 106(2): p. 203-15. 
27. Mullick, A., et al., The cumate gene-switch: a system for regulated expression in mammalian cells. 
BMC Biotechnol, 2006. 6: p. 43. 
28. Yee, J.C., et al., Genomic and proteomic exploration of CHO and hybridoma cells under sodium 
butyrate treatment. Biotechnol Bioeng, 2008. 99(5): p. 1186-204. 
  
80 
29. Baycin-Hizal, D., et al., Proteomic analysis of Chinese hamster ovary cells. J Proteome Res, 2012. 
11(11): p. 5265-76. 
30. Meleady, P., et al., Utilization and evaluation of CHO-specific sequence databases for mass 
spectrometry based proteomics. Biotechnol Bioeng, 2012. 109(6): p. 1386-94. 
31. Orellana, C.A., et al., High-antibody-producing Chinese hamster ovary cells up-regulate 
intracellular protein transport and glutathione synthesis. J Proteome Res, 2015. 14(2): p. 609-18. 
32. Chong, W.P., et al., LC-MS-based metabolic characterization of high monoclonal antibody-
producing Chinese hamster ovary cells. Biotechnol Bioeng, 2012. 109(12): p. 3103-11. 
33. Hammond, W.A., A. Swaika, and K. Mody, Pharmacologic resistance in colorectal cancer: a 
review. Ther Adv Med Oncol, 2016. 8(1): p. 57-84. 
34. Seymour, M.T., et al., Different strategies of sequential and combination chemotherapy for patients 
with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. 
Lancet, 2007. 370(9582): p. 143-52. 
35. Hsiang, Y.H., M.G. Lihou, and L.F. Liu, Arrest of replication forks by drug-stabilized 
topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer 
Res, 1989. 49(18): p. 5077-82. 
36. Pommier, Y., Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer, 2006. 
6(10): p. 789-802. 
37. Wall, M.E., Camptothecin and taxol: discovery to clinic. Med Res Rev, 1998. 18(5): p. 299-314. 
38. Cummings, J., et al., Factors influencing the cellular accumulation of SN-38 and camptothecin. 
Cancer Chemother Pharmacol, 2002. 49(3): p. 194-200. 
39. Hsiang, Y.H., et al., Camptothecin induces protein-linked DNA breaks via mammalian DNA 
topoisomerase I. J Biol Chem, 1985. 260(27): p. 14873-8. 
40. Longley, D.B. and P.G. Johnston, Molecular mechanisms of drug resistance. J Pathol, 2005. 
205(2): p. 275-92. 
41. Cummings, J., et al., Enhanced clearance of topoisomerase I inhibitors from human colon cancer 
cells by glucuronidation. Biochem Pharmacol, 2002. 63(4): p. 607-13. 
42. Gottesman, M.M., T. Fojo, and S.E. Bates, Multidrug resistance in cancer: role of ATP-dependent 
transporters. Nat Rev Cancer, 2002. 2(1): p. 48-58. 
  
81 
43. Goldman, B., Multidrug resistance: can new drugs help chemotherapy score against cancer? J 
Natl Cancer Inst, 2003. 95(4): p. 255-7. 
44. Thomas, H. and H.M. Coley, Overcoming multidrug resistance in cancer: an update on the clinical 
strategy of inhibiting p-glycoprotein. Cancer Control, 2003. 10(2): p. 159-65. 
45. Chiang, S.C., J. Carroll, and S.F. El-Khamisy, TDP1 serine 81 promotes interaction with DNA 
ligase IIIalpha and facilitates cell survival following DNA damage. Cell Cycle, 2010. 9(3): p. 588-
595. 
46. Zhou, T., et al., Tyrosyl-DNA phosphodiesterase and the repair of 3'-phosphoglycolate-terminated 
DNA double-strand breaks. DNA Repair (Amst), 2009. 8(8): p. 901-11. 
47. Alagoz, M., et al., DNA repair and resistance to topoisomerase I inhibitors: mechanisms, 
biomarkers and therapeutic targets. Curr Med Chem, 2012. 19(23): p. 3874-85. 
48. Walker, S., et al., Development of an oligonucleotide-based fluorescence assay for the 
identification of tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors. Anal Biochem, 2014. 454: 
p. 17-22. 
49. Meisenberg, C., et al., Clinical and cellular roles for TDP1 and TOP1 in modulating colorectal 
cancer response to irinotecan. Mol Cancer Ther, 2015. 14(2): p. 575-85. 
50. Lengauer, C., K.W. Kinzler, and B. Vogelstein, Genetic instabilities in human cancers. Nature, 
1998. 396(6712): p. 643-9. 
51. Berg, S., Alterations in Colorectal Cancer Cell-extracellular Matrix Interactions Upon Acquisition 
of Chemotherapy Resistance. 2015, University of Waterloo: Waterloo. p. 125. 
52. van den Heuvel-Eibrink, M.M., et al., Increased expression of the breast cancer resistance protein 
(BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia, 2002. 16(5): p. 833-
9. 
53. Chan, L.M., S. Lowes, and B.H. Hirst, The ABCs of drug transport in intestine and liver: efflux 
proteins limiting drug absorption and bioavailability. Eur J Pharm Sci, 2004. 21(1): p. 25-51. 
54. Mathijssen, R.H., et al., Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin 
Cancer Res, 2003. 9(9): p. 3246-53. 
55. Candeil, L., et al., ABCG2 overexpression in colon cancer cells resistant to SN-38 and in 
irinotecan-treated metastases. Int J Cancer, 2004. 109(6): p. 848-54. 
56. Petitprez, A., et al., Acquired irinotecan resistance is accompanied by stable modifications of cell 
cycle dynamics independent of MSI status. Int J Oncol, 2013. 42(5): p. 1644-53. 
  
82 
57. Yu, M., A. Ocana, and I.F. Tannock, Reversal of ATP-binding cassette drug transporter activity to 
modulate chemoresistance: why has it failed to provide clinical benefit? Cancer Metastasis Rev, 
2013. 32(1-2): p. 211-27. 
58. Ballesta, A., et al., A combined experimental and mathematical approach for molecular-based 
optimization of irinotecan circadian delivery. PLoS Comput Biol, 2011. 7(9): p. e1002143. 
59. Ruoslahti, E., et al., Fibroblast surface antigen: a new serum protein. Biochim Biophys Acta, 1973. 
322(2): p. 352-8. 
60. Hynes, R.O., The emergence of integrins: a personal and historical perspective. Matrix Biol, 2004. 
23(6): p. 333-40. 
61. Hynes, R.O., Integrins: bidirectional, allosteric signaling machines. Cell, 2002. 110(6): p. 673-87. 
62. Kim, C., et al., Basic amino-acid side chains regulate transmembrane integrin signalling. Nature, 
2011. 481(7380): p. 209-13. 
63. Kim, C., F. Ye, and M.H. Ginsberg, Regulation of integrin activation. Annu Rev Cell Dev Biol, 
2011. 27: p. 321-45. 
64. Shattil, S.J., C. Kim, and M.H. Ginsberg, The final steps of integrin activation: the end game. Nat 
Rev Mol Cell Biol, 2010. 11(4): p. 288-300. 
65. Bartolome, R.A., et al., Cadherin-17 interacts with alpha2beta1 integrin to regulate cell 
proliferation and adhesion in colorectal cancer cells causing liver metastasis. Oncogene, 2014. 
33(13): p. 1658-69. 
66. Pelillo, C., et al., Colorectal Cancer Metastases Settle in the Hepatic Microenvironment Through 
alpha5beta1 Integrin. J Cell Biochem, 2015. 116(10): p. 2385-96. 
67. Huhtala, P., et al., Cooperative signaling by alpha 5 beta 1 and alpha 4 beta 1 integrins regulates 
metalloproteinase gene expression in fibroblasts adhering to fibronectin. J Cell Biol, 1995. 129(3): 
p. 867-79. 
68. Yang, B., et al., Clinicopathological and prognostic significance of alpha5beta1-integrin and 
MMP-14 expressions in colorectal cancer. Neoplasma, 2013. 60(3): p. 254-61. 
69. Frisch, S.M. and H. Francis, Disruption of epithelial cell-matrix interactions induces apoptosis. J 
Cell Biol, 1994. 124(4): p. 619-26. 
70. Damiano, J.S., et al., Cell adhesion mediated drug resistance (CAM-DR): role of integrins and 
resistance to apoptosis in human myeloma cell lines. Blood, 1999. 93(5): p. 1658-67. 
  
83 
71. De Toni, F., et al., A crosstalk between the Wnt and the adhesion-dependent signaling pathways 
governs the chemosensitivity of acute myeloid leukemia. Oncogene, 2006. 25(22): p. 3113-22. 
72. Ross, P.L., et al., Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-
reactive isobaric tagging reagents. Mol Cell Proteomics, 2004. 3(12): p. 1154-69. 
73. Zieske, L.R., A perspective on the use of iTRAQ reagent technology for protein complex and 
profiling studies. J Exp Bot, 2006. 57(7): p. 1501-8. 
74. Johnson, R.S., et al., Novel fragmentation process of peptides by collision-induced decomposition 
in a tandem mass spectrometer: differentiation of leucine and isoleucine. Anal Chem, 1987. 59(21): 
p. 2621-5. 
75. Ma, B., et al., PEAKS: powerful software for peptide de novo sequencing by tandem mass 
spectrometry. Rapid Commun Mass Spectrom, 2003. 17(20): p. 2337-42. 
76. Roepstorff, P. and J. Fohlman, Proposal for a common nomenclature for sequence ions in mass 
spectra of peptides. Biomed Mass Spectrom, 1984. 11(11): p. 601. 
77. Zhang, J., et al., PEAKS DB: de novo sequencing assisted database search for sensitive and 
accurate peptide identification. Mol Cell Proteomics, 2012. 11(4): p. M111 010587. 
78. Karpievitch, Y.V., et al., Normalization of peak intensities in bottom-up MS-based proteomics 
using singular value decomposition. Bioinformatics, 2009. 25(19): p. 2573-80. 
79. Bolstad, B.M., et al., A comparison of normalization methods for high density oligonucleotide array 
data based on variance and bias. Bioinformatics, 2003. 19(2): p. 185-93. 
80. Smyth, G.K., Linear models and empirical bayes methods for assessing differential expression in 
microarray experiments. Stat Appl Genet Mol Biol, 2004. 3: p. Article3. 
81. Faul, F., et al., Statistical power analyses using G*Power 3.1: tests for correlation and regression 
analyses. Behav Res Methods, 2009. 41(4): p. 1149-60. 
82. Benjamini, Y. and Y. Hochberg, Controlling the False Discovery Rate: A Practical and Powerful 
Approach to Multiple Testing. Journal of the Royal Statistical Society. Series B (Methodological), 
1995. 57(1): p. 289-300. 
83. Gentleman, R.C., et al., Bioconductor: open software development for computational biology and 
bioinformatics. Genome Biol, 2004. 5(10): p. R80. 
84. Dennis, G., Jr., et al., DAVID: Database for Annotation, Visualization, and Integrated Discovery. 
Genome Biol, 2003. 4(5): p. P3. 
  
84 
85. Huang da, W., B.T. Sherman, and R.A. Lempicki, Systematic and integrative analysis of large gene 
lists using DAVID bioinformatics resources. Nat Protoc, 2009. 4(1): p. 44-57. 
86. Huang, D.W., et al., DAVID Bioinformatics Resources: expanded annotation database and novel 
algorithms to better extract biology from large gene lists. Nucleic Acids Res, 2007. 35(Web Server 
issue): p. W169-75. 
87. Ciardiello, F. and F. De Vita, Epidermal growth factor receptor (EGFR) inhibitors in cancer 
therapy. Prog Drug Res, 2005. 63: p. 93-114. 
88. Poulain, A., et al., Rapid protein production from stable CHO cell pools using plasmid vector and 
the cumate gene-switch. J Biotechnol, 2017. 255: p. 16-27. 
89. Han, J.C. and G.Y. Han, A procedure for quantitative determination of tris(2-
carboxyethyl)phosphine, an odorless reducing agent more stable and effective than dithiothreitol. 
Anal Biochem, 1994. 220(1): p. 5-10. 
90. Bradford, M.M., A rapid and sensitive method for the quantitation of microgram quantities of 
protein utilizing the principle of protein-dye binding. Anal Biochem, 1976. 72: p. 248-54. 
91. Wisniewski, J.R., A. Zougman, and M. Mann, Combination of FASP and StageTip-based 
fractionation allows in-depth analysis of the hippocampal membrane proteome. J Proteome Res, 
2009. 8(12): p. 5674-8. 
92. Wisniewski, J.R., et al., Universal sample preparation method for proteome analysis. Nat Methods, 
2009. 6(5): p. 359-62. 
93. Desjardins, P., J.B. Hansen, and M. Allen, Microvolume protein concentration determination using 
the NanoDrop 2000c spectrophotometer. J Vis Exp, 2009(33). 
94. Ritchie, M.E., et al., limma powers differential expression analyses for RNA-sequencing and 
microarray studies. Nucleic Acids Res, 2015. 43(7): p. e47. 
95. Challa, A.A. and B. Stefanovic, A novel role of vimentin filaments: binding and stabilization of 
collagen mRNAs. Mol Cell Biol, 2011. 31(18): p. 3773-89. 
96. Zeng, Y., et al., The cancer/testis antigen prostate-associated gene 4 (PAGE4) is a highly 
intrinsically disordered protein. J Biol Chem, 2011. 286(16): p. 13985-94. 
97. Jia, D., et al., Phenotypic Plasticity and Cell Fate Decisions in Cancer: Insights from Dynamical 
Systems Theory. Cancers (Basel), 2017. 9(7). 
98. Kulkarni, P., et al., Prostate-associated gene 4 (PAGE4), an intrinsically disordered cancer/testis 
antigen, is a novel therapeutic target for prostate cancer. Asian J Androl, 2016. 18(5): p. 695-703. 
  
85 
99. Iavarone, C., et al., PAGE4 is a cytoplasmic protein that is expressed in normal prostate and in 
prostate cancers. Mol Cancer Ther, 2002. 1(5): p. 329-35. 
100. Duan, Z., et al., Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human 
cancer cell lines. Clin Cancer Res, 2003. 9(7): p. 2778-85. 
101. Rajagopalan, K., et al., The Stress-response protein prostate-associated gene 4, interacts with c-
Jun and potentiates its transactivation. Biochim Biophys Acta, 2014. 1842(2): p. 154-63. 
102. Kato, T., et al., Increased expression of insulin-like growth factor-II messenger RNA-binding 
protein 1 is associated with tumor progression in patients with lung cancer. Clin Cancer Res, 2007. 
13(2 Pt 1): p. 434-42. 
103. Vikesaa, J., et al., RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO 
J, 2006. 25(7): p. 1456-68. 
104. Livingstone, C., IGF2 and cancer. Endocr Relat Cancer, 2013. 20(6): p. R321-39. 
105. Clemmons, D.R., Insulin-like growth factor binding proteins and their role in controlling IGF 
actions. Cytokine Growth Factor Rev, 1997. 8(1): p. 45-62. 
106. Jones, J.I., et al., Insulin-like growth factor binding protein 1 stimulates cell migration and binds 
to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci U S A, 
1993. 90(22): p. 10553-7. 
107. Sinha, P., et al., Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-
sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and 
microsequencing of drug-resistant human adenocarcinoma of the pancreas. Electrophoresis, 1999. 
20(14): p. 2952-60. 
108. Samyesudhas, S.J., L. Roy, and K.D. Cowden Dahl, Differential expression of ARID3B in normal 
adult tissue and carcinomas. Gene, 2014. 543(1): p. 174-80. 
109. Honda, K., et al., Actinin-4 increases cell motility and promotes lymph node metastasis of 
colorectal cancer. Gastroenterology, 2005. 128(1): p. 51-62. 
110. Grass, G.D., et al., CD147: regulator of hyaluronan signaling in invasiveness and chemoresistance. 
Adv Cancer Res, 2014. 123: p. 351-73. 
111. Shay, G., C.C. Lynch, and B. Fingleton, Moving targets: Emerging roles for MMPs in cancer 
progression and metastasis. Matrix Biol, 2015. 44-46: p. 200-6. 
112. Moll, R., et al., Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by 
monoclonal antibodies. Am J Pathol, 1992. 140(2): p. 427-47. 
  
86 
113. Kust, D., et al., Cytokeratin 20 positive cells in blood of colorectal cancer patients as an 
unfavorable prognostic marker. Acta Clin Belg, 2016. 71(4): p. 235-43. 
114. Kim, M.J., et al., Profilin 2 promotes migration, invasion, and stemness of HT-29 human colorectal 
cancer stem cells. Biosci Biotechnol Biochem, 2015. 79(9): p. 1438-46. 
115. Mooney, S.M., et al., Creatine kinase brain overexpression protects colorectal cells from various 
metabolic and non-metabolic stresses. J Cell Biochem, 2011. 112(4): p. 1066-75. 
116. Lagresle-Peyrou, C., et al., X-linked primary immunodeficiency associated with hemizygous 
mutations in the moesin (MSN) gene. J Allergy Clin Immunol, 2016. 138(6): p. 1681-1689 e8. 
117. O'Brien, C.A., et al., A human colon cancer cell capable of initiating tumour growth in 
immunodeficient mice. Nature, 2007. 445(7123): p. 106-10. 
118. Loeffler, M., et al., Targeting tumor-associated fibroblasts improves cancer chemotherapy by 
increasing intratumoral drug uptake. J Clin Invest, 2006. 116(7): p. 1955-62. 
119. Azmi, A.S., B. Bao, and F.H. Sarkar, Exosomes in cancer development, metastasis, and drug 
resistance: a comprehensive review. Cancer Metastasis Rev, 2013. 32(3-4): p. 623-42. 
120. Lai, M.D. and J. Xu, Ribosomal proteins and colorectal cancer. Curr Genomics, 2007. 8(1): p. 43-
9. 
 
  
  
87 
Appendix A 
Table A: List of CHO proteins identified with p-values smaller than 0.05 
Gene Symbol Protein GI Description p-value log FC 
- - eg2-hfc1 [Lama glama-Homo sapiens] 0.000 1.502 
Upar 354492547 urokinase plasminogen activator surface receptor  partial   0.000 -0.300 
Trmt112 354498436 tRNA methyltransferase 112 homolog   0.001 0.333 
LOC100754718 354492600 protein phosphatase 1 regulatory subunit 12A-like   0.001 -0.088 
Mrpl55 354482471  39S ribosomal protein L55  mitochondrial-like   0.002 -0.439 
Gstp1 350537543 glutathione S-transferase P 1   0.002 -0.178 
Rps7 354495303 40S ribosomal protein S7-like   0.002 0.163 
Lsm3 354465501 U6 snRNA-associated Sm-like protein LSm3-like   0.003 -0.203 
Fkbp11 354497358 peptidyl-prolyl cis-trans isomerase FKBP11-like   0.003 0.260 
LOC100758296 354491098 poly(U)-binding-splicing factor PUF60-like   0.004 -0.134 
Dnaja1 354498827 LOW QUALITY PROTEIN: dnaJ homolog subfamily A member 
1   
0.005 -0.143 
Tra2b 354484188 transformer-2 protein homolog beta-like   0.006 0.281 
Bgn 354488869 biglycan-like   0.006 -0.117 
Ganab 354493306 neutral alpha-glucosidase AB isoform 1   0.006 0.205 
Lamc1 354481424 laminin subunit gamma-1   0.006 -0.287 
Synj1 354466272 synaptojanin-1 isoform 2   0.008 -0.120 
Fam3a 354500495 protein FAM3A-like   0.008 -0.204 
Vim 354482483 vimentin   0.008 -0.266 
LOC100756788 354466573 hematological and neurological expressed 1 protein-like   0.009 -0.253 
LOC100772255 354481494 stress-associated endoplasmic reticulum protein 1-like  
partial   
0.009 0.345 
Wdr61 354471439 WD repeat-containing protein 61-like isoform 2   0.010 -0.135 
G3bp2 354499120 ras GTPase-activating protein-binding protein 2 isoform 1   0.011 -0.064 
Psma1 354488597 proteasome subunit alpha type-1-like   0.011 -0.103 
Gfm1 354496448 elongation factor G  mitochondrial-like   0.012 -0.072 
LOC100753707 354507225 40S ribosomal protein S6-like  partial   0.012 0.212 
Epb4.1l2 354494678 band 4.1-like protein 2   0.013 -0.087 
Col6a1 354476788 collagen alpha-1(VI) chain   0.013 -0.162 
Gcsh 354493382 glycine cleavage system H protein  mitochondrial-like   0.013 -0.126 
LOC100755252 354474224 thymidylate kinase-like   0.014 -0.144 
Mesd 354499297 LDLR chaperone MESD-like   0.014 -0.078 
Asna1 354479529 ATPase Asna1   0.014 -0.376 
Hmgcs1 354485654 hydroxymethylglutaryl-CoA synthase  cytoplasmic-like   0.015 -0.137 
Rbm12 354477974 RNA-binding protein 12   0.016 -0.105 
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Tuba1c 345842428 tubulin alpha-1C chain   0.016 -0.158 
LOC100766608 354486253 26S protease regulatory subunit 6B-like   0.016 -0.113 
LOC100771019 354488039 polyadenylate-binding protein 2-like   0.017 -0.244 
Rrbp1 354468128 ribosome-binding protein 1   0.018 0.079 
LOC100774114 354492313 60S ribosomal protein L28-like   0.019 0.106 
Mthfd1l 354466920 monofunctional C1-tetrahydrofolate synthase  
mitochondrial   
0.019 -0.130 
LOC100763481 354477579 hypothetical protein LOC100763481   0.021 0.199 
Col6a2 354476782 collagen alpha-2(VI) chain isoform 1   0.021 -0.138 
Fh 354475349 fumarate hydratase  mitochondrial-like   0.022 -0.107 
Tkt 354467411 transketolase-like   0.022 0.085 
Glul 354481440 glutamine synthetase-like   0.023 0.282 
Ube2o 354489489 ubiquitin-conjugating enzyme E2 O   0.023 -0.277 
LOC100755568 354484186 insulin-like growth factor 2 mRNA-binding protein 2-like 
isoform 2   
0.025 -0.270 
LOC100767827 354507734 UDP-glucose 6-dehydrogenase-like  partial   0.026 -0.076 
LOC100760000 354481833 acetyl-CoA acetyltransferase  cytosolic-like   0.026 -0.069 
Sh3pxd2a 354500209 SH3 and PX domain-containing protein 2A   0.028 -0.160 
LOC100769327 354499764 UPF0568 protein C14orf166 homolog   0.028 -0.224 
Rbck1 354498892 ranBP-type and C3HC4-type zinc finger-containing protein 1  
partial   
0.029 -0.112 
LOC100774828 354504685 methylosome protein 50-like   0.030 -0.196 
Tsr2 354476053 pre-rRNA-processing protein TSR2 homolog   0.031 -0.119 
Aip 354495724 AH receptor-interacting protein   0.031 -0.126 
Slc27a4 354499491 long-chain fatty acid transport protein 4   0.032 -0.233 
Itga5 354497226 integrin alpha-5   0.033 -0.102 
Lta4h 354478523 leukotriene A-4 hydrolase   0.033 -0.100 
Icam1 350539683 intercellular adhesion molecule 1   0.033 -0.220 
Anxa1 354496812 annexin A1-like   0.035 0.172 
Dnase2 354479537 deoxyribonuclease-2-alpha-like   0.035 -0.186 
Fn1 354494385 fibronectin isoform 3   0.037 -0.131 
COX2 91176206 cytochrome c oxidase subunit II   0.037 -0.270 
Cd44 354470417 CD44 antigen isoform 3   0.039 -0.146 
Srsf3 354484028 serine/arginine-rich splicing factor 3-like   0.039 0.086 
Rpl31 354482378 60S ribosomal protein L31-like   0.040 0.130 
LOC100762308 354473557 protein-L-isoaspartate(D-aspartate) O-methyltransferase-
like   
0.040 -0.076 
Pam16 354488489 coronin-7   0.040 -0.104 
Hspg 354483018 LOW QUALITY PROTEIN: basement membrane-specific 
heparan sulfate proteoglycan core protein   
0.040 -0.237 
Erbb2ip 354474057 protein LAP2   0.041 -0.330 
LOC100757077 354503831 protein CTLA-2-beta-like   0.042 -0.238 
Ddt 354492004 D-dopachrome decarboxylase-like   0.042 -0.083 
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LOC100762458 354495283 nuclear mitotic apparatus protein 1-like  partial   0.043 -0.099 
Ccdc115 354491621 coiled-coil domain-containing protein 115-like   0.044 -0.212 
LOC100751694 354502651 14-3-3 protein theta-like   0.044 -0.193 
Sf3b5 354475529 splicing factor 3B subunit 5-like   0.046 -0.080 
Dctpp1 354506130 LOW QUALITY PROTEIN: dCTP pyrophosphatase 1-like   0.046 -0.379 
Pea15 349501078 astrocytic phosphoprotein PEA-15   0.048 -0.151 
Tom1 354499827 target of Myb protein 1   0.049 -0.356 
Tubb4b 346644707 tubulin beta-2C chain   0.049 -0.125 
Ltv1 354475527 protein LTV1 homolog   0.049 0.076 
Galm 354488923 aldose 1-epimerase-like   0.049 -0.275 
LOC100756352 354486710 hypothetical protein LOC100756352   0.050 -0.096 
 
  
  
90 
Appendix B 
Table B: List of significantly differentially expressed proteins in HT-29S cell line with 5% Benjamini-
Hochberg FDR correction. 
Gene 
Symbol 
Protein GI Description P-value logFC 
PAGE4 5901986 P antigen family member 4  1.2E-03 2.256 
UCHL1 189067502 unnamed protein product  2.2E-05 1.660 
FABP5 4557581 fatty acid-binding protein  epidermal  2.8E-03 1.255 
IGF2BP1 56237027 insulin-like growth factor 2 mRNA-binding protein 1 
isoform 1  
3.5E-04 1.196 
FABP7 4557585 fatty acid-binding protein  brain isoform 1  1.1E-03 1.177 
ARID3A 56799575 DRIL3  3.3E-03 1.151 
AKAP2 194385574 unnamed protein product  3.5E-07 1.093 
EPB41L3 767997596 band 4.1-like protein 3 isoform X11  1.8E-04 0.981 
PDLIM1 189054550 Carboxyl Terminal LIM Domain Protein 1  3.0E-06 0.892 
ERVH48-1 819231746 suppressyn precursor  4.3E-03 0.847 
TPM1 578827355 tropomyosin alpha-1 chain isoform X5  1.8E-03 0.846 
CXorf67 42821110 uncharacterized protein CXorf67  1.0E-02 0.804 
SET 119608226 SET translocation (myeloid leukemia-associated)  
isoform CRA_c  
6.9E-04 0.800 
ARG2 4502215 arginase-2  mitochondrial precursor  8.0E-03 0.789 
MRFAP1 194384244 unnamed protein product  8.5E-03 0.770 
QPRT 1060907 quinolinate phosphoribosyl transferase  8.2E-05 0.760 
GINS4 14150122 DNA replication complex GINS protein SLD5  1.9E-03 0.749 
KLRG2 51094790 FLJ44186 protein  1.1E-02 0.748 
NENF 7019545 neudesin precursor  7.2E-07 0.739 
MPP1 119593065 membrane protein  palmitoylated 1  55kDa  isoform 
CRA_e  
2.4E-05 0.734 
FSCN1 14043297 Similar to singed (Drosophila)-like (sea urchin fascin 
homolog like)  partial  
6.9E-04 0.719 
PITPNA 767992345 phosphatidylinositol transfer protein alpha isoform 
isoform X1  
9.5E-03 0.708 
CLIC4 194376454 unnamed protein product  4.3E-03 0.708 
PTK7 22902128 inactive tyrosine-protein kinase 7 isoform c 
precursor  
4.7E-03 0.703 
LCP1 62898171 L-plastin variant  3.8E-03 0.672 
KRT7 767974195 keratin  type II cytoskeletal 7 isoform X1  3.9E-04 0.671 
ATP5B 32189394 ATP synthase subunit beta  mitochondrial precursor  5.8E-06 0.667 
RAE1 4506399 mRNA export factor  5.8E-05 0.666 
TRIM28 5032179 transcription intermediary factor 1-beta  1.8E-03 0.661 
ALAD 248841 delta-aminolevulinate dehydratase  9.4E-03 0.649 
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ATIC 20127454 bifunctional purine biosynthesis protein PURH  1.0E-03 0.628 
SH2D4A 292658785 SH2 domain-containing protein 4A isoform b  1.4E-04 0.616 
BCAT1 296010902 branched-chain-amino-acid aminotransferase  
cytosolic isoform 3  
4.1E-04 0.591 
CTSV 189053498 unnamed protein product  1.7E-03 0.589 
TACSTD2 49457514 TACSTD2  3.5E-03 0.588 
NPC2 189065149 unnamed protein product  2.3E-03 0.588 
ALDH6A1 515870067 methylmalonate-semialdehyde dehydrogenase 
[acylating]  mitochondrial isoform 3  
1.0E-02 0.586 
LRP2 767918153 low-density lipoprotein receptor-related protein 2 
isoform X1  
2.1E-03 0.584 
PALLD 260656032 palladin isoform 3  5.4E-04 0.581 
PHGDH 767903710 D-3-phosphoglycerate dehydrogenase isoform X1  5.3E-04 0.580 
PLIN2 194382232 unnamed protein product  1.3E-03 0.578 
C1orf52 19550363 gm117 form A  7.9E-05 0.572 
CNPY2 7657176 protein canopy homolog 2 isoform 1 precursor  1.5E-02 0.556 
SNX2 2827434 sorting nexin 2  2.6E-04 0.554 
LY6E 119602691 lymphocyte antigen 6 complex  locus E  isoform 
CRA_a  
1.6E-03 0.543 
LAMB1 186837 laminin B1  2.7E-05 0.541 
UBAC1 5759309 putative glialblastoma cell differentiation-related 
protein  
2.4E-03 0.536 
RAP1B 354459356 ras-related protein Rap-1b isoform 4  2.4E-03 0.535 
TPT1 15214610 Tumor protein  translationally-controlled 1  3.6E-07 0.532 
AKAP12 60219476 hypothetical protein  2.8E-05 0.530 
CCT4 375477430 T-complex protein 1 subunit delta isoform b  7.4E-03 0.529 
RNF114 8923898 E3 ubiquitin-protein ligase RNF114  1.2E-03 0.529 
AHSA1 6912280 activator of 90 kDa heat shock protein ATPase 
homolog 1 isoform 1  
4.5E-05 0.524 
ACAT2 12653279 ACAT2 protein  4.8E-03 0.524 
IMPDH2 307066 inosine-5'-monophosphate dehydrogenase (EC 
1.1.1.205)  
1.9E-05 0.523 
BSG 31076333 CD147  1.3E-05 0.519 
HEBP1 20336761 heme-binding protein 1  2.3E-03 0.519 
MTHFD1 14602585 Methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 1  methenyltetrahydrofolate 
cyclohydrolase  formyltetrahydrofolate synthetase  
1.0E-04 0.518 
HSPE1 4504523 10 kDa heat shock protein  mitochondrial  7.1E-03 0.518 
PLS3 62897161 plastin 3 variant  4.7E-03 0.509 
SNRPD1 32959908 small nuclear ribonucleoprotein Sm D1  6.7E-03 0.506 
DFFA 14043461 DNA fragmentation factor  45kDa  alpha polypeptide  6.0E-03 0.500 
SLC39A14 16041779 SLC39A14 protein  5.7E-03 0.500 
SNRPD2 237649049 small nuclear ribonucleoprotein Sm D2 isoform 2  4.5E-03 0.494 
ANXA3 4826643 annexin A3  4.6E-03 0.492 
SKA3 260763912 spindle and kinetochore-associated protein 3 
isoform 2  
1.7E-03 0.490 
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KRAS 15488883 V-Ki-ras2 Kirsten rat sarcoma viral oncogene 
homolog  
1.8E-03 0.487 
ILF2 284261 interleukin enhancer-binding factor ILF-2 - human 1.9E-03 0.483 
PGM3 119569054 phosphoglucomutase 3  isoform CRA_c  1.4E-03 0.482 
REPS1 18203725 REPS1 protein  2.5E-05 0.480 
SUGT1 119572429 SGT1  suppressor of G2 allele of SKP1 (S. cerevisiae)  
isoform CRA_b  
6.7E-03 0.478 
SPAG9 76779789 SPAG9 protein  5.0E-03 0.474 
KIF2C 663071031 kinesin-like protein KIF2C isoform 2  3.8E-03 0.469 
PSMC3 62896529 proteasome 26S ATPase subunit 3 variant  1.3E-04 0.467 
POP7 153791431 ribonuclease P protein subunit p20  1.2E-02 0.463 
QKI 7542353 QUAKING isoform 4  7.3E-04 0.461 
HNRNPA1 194382016 unnamed protein product  1.6E-02 0.461 
PRDX6 4758638 peroxiredoxin-6  2.2E-03 0.458 
RPRD1A 119621775 hypothetical protein FLJ10656  isoform CRA_d  3.0E-03 0.458 
NASP 767904447 nuclear autoantigenic sperm protein isoform X2  1.4E-03 0.448 
SOD1 4507149 superoxide dismutase [Cu-Zn] 1.1E-02 0.444 
UBQLN1 12060171 DA41  4.3E-04 0.443 
CLNS1A 909618069 methylosome subunit pICln isoform d  1.1E-05 0.435 
SNX3 4507143 sorting nexin-3 isoform a  2.9E-03 0.435 
FABP3 4758328 fatty acid-binding protein  heart isoform 2  3.7E-03 0.434 
RPRD1B 21708061 Regulation of nuclear pre-mRNA domain containing 
1B  
6.5E-05 0.434 
RPA3 119614009 replication protein A3  14kDa  isoform CRA_a  7.6E-04 0.426 
TPM4 4507651 tropomyosin alpha-4 chain isoform Tpm4.2cy  2.9E-04 0.421 
FARSA 194386000 unnamed protein product  2.2E-05 0.420 
CCAR2 767951088 cell cycle and apoptosis regulator protein 2 isoform 
X1  
2.0E-03 0.419 
LUC7L 14336684 putative RNA binding protein  4.7E-05 0.419 
NELFA 119602953 Wolf-Hirschhorn syndrome candidate 2  isoform 
CRA_c  
1.0E-02 0.417 
KIAA1143 33468965 uncharacterized protein KIAA1143 isoform 1  1.8E-03 0.417 
PFAS 31657129 phosphoribosylformylglycinamidine synthase  1.2E-04 0.417 
DUT 4503423 deoxyuridine 5'-triphosphate nucleotidohydrolase  
mitochondrial isoform 2  
1.4E-02 0.415 
GARS 943350815 glycine--tRNA ligase isoform 2  1.2E-02 0.411 
THRAP3 1009287627 thyroid hormone receptor-associated protein 3 
isoform 2  
1.4E-02 0.404 
PMPCB 40226469 PMPCB protein  partial  2.2E-04 0.403 
FAM207A 948284426 protein FAM207A isoform 7  5.4E-03 0.402 
CHORDC1 6581056 CHORD containing protein-1  1.4E-02 0.400 
CA2 922664887 carbonic anhydrase 2 - Chain A  Surface Lysine 
Acetylated Human Carbonic Anhydrase Ii In Complex 
With A Sulfamate-based Inhibitor 
4.3E-03 0.400 
VCP 6005942 transitional endoplasmic reticulum ATPase  1.5E-02 0.400 
ATP6V1B2 13938355 ATP6V1B2 protein  partial  9.3E-03 0.398 
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VTA1 556503352 vacuolar protein sorting-associated protein VTA1 
homolog isoform b  
2.2E-03 0.397 
HPDL 14249394 4-hydroxyphenylpyruvate dioxygenase-like protein  5.1E-03 0.396 
PDE12 767922620 2' 5'-phosphodiesterase 12 isoform X1  6.9E-03 0.395 
SHTN1 385198097 shootin-1 isoform e  4.6E-04 0.395 
FDX1 182747 ferredoxin  partial  1.3E-02 0.391 
PARD6B 62955042 partitioning defective 6 homolog beta  9.8E-03 0.391 
PRPF6 119595583 chromosome 20 open reading frame 14  isoform 
CRA_d  
7.4E-03 0.389 
MCM3 20384693 cervical cancer proto-oncogene 5  1.3E-04 0.389 
SNRPGP15 205829943 RecName: Full=Putative small nuclear 
ribonucleoprotein G-like protein 15 
5.0E-04 0.388 
MAPRE1 194386362 Microtubule Associated Protein RP/EB Family 
Member 1  
8.9E-05 0.387 
WDR77 951233338 methylosome protein 50 isoform 4  7.9E-03 0.385 
RBPMS 5803141 RNA-binding protein with multiple splicing isoform A  1.1E-03 0.384 
CNOT3 6599188 hypothetical protein  9.1E-05 0.384 
NOC4L 119618951 nucleolar complex associated 4 homolog (S. 
cerevisiae)  isoform CRA_b  
1.1E-02 0.383 
APEH 530372380 acylamino-acid-releasing enzyme isoform X6  1.3E-02 0.379 
EIF4B 194388916 unnamed protein product  1.0E-02 0.378 
DIS3 190014623 exosome complex exonuclease RRP44 isoform a  1.5E-03 0.376 
ERP29 5803013 endoplasmic reticulum resident protein 29 isoform 1 
precursor  
4.5E-04 0.374 
RBM26 767977967 RNA-binding protein 26 isoform X16  4.9E-03 0.373 
AIM1L 767904873 absent in melanoma 1-like protein isoform X4  4.1E-05 0.370 
XAGE2 19747283 X antigen family member 2  1.4E-02 0.369 
PROSC 119583764 proline synthetase co-transcribed homolog 
(bacterial)  isoform CRA_a  
4.3E-04 0.365 
LGALS3 28071074 unnamed protein product  6.6E-04 0.363 
DAG1 294997282 dystroglycan preproprotein  5.2E-03 0.362 
GNL3 119585654 guanine nucleotide binding protein-like 3 (nucleolar)  
isoform CRA_b  
1.5E-02 0.360 
OTUD5 209977067 OTU domain-containing protein 5 isoform c  1.1E-02 0.359 
HLA-A 156601507 MHC class I antigen  6.2E-05 0.358 
YAP1 530788252 transcriptional coactivator YAP1 isoform 9  1.5E-03 0.356 
CLIC3 40288290 chloride intracellular channel protein 3  6.8E-06 0.354 
UGP2 449441 UDP-glucose pyrophosphorylase 1.1E-02 0.353 
CD2AP 530381720 CD2-associated protein isoform X1  3.3E-04 0.353 
WASF1 4507913 wiskott-Aldrich syndrome protein family member 1  9.9E-03 0.351 
SERPINH1 32454741 serpin H1 precursor  6.0E-04 0.350 
RAD23B 194374237 unnamed protein product  3.5E-03 0.337 
PSMC6 195539395 26S protease regulatory subunit 10B  4.2E-04 0.335 
PUS1 767975389 tRNA pseudouridine synthase A  mitochondrial 
isoform X2  
4.3E-04 0.326 
VCL 24657579 Vinculin  5.5E-03 0.325 
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EEF1A1 62896661 eukaryotic translation elongation factor 1 alpha 1 
variant  
5.3E-04 0.325 
PDCD6IP 22027538 programmed cell death 6-interacting protein 
isoform 1  
8.5E-03 0.323 
SNX6 33337751 MSTP010  1.0E-03 0.321 
HMGCS1 767934415 hydroxymethylglutaryl-CoA synthase  cytoplasmic 
isoform X2  
7.5E-03 0.317 
PPP1R12A 767974349 protein phosphatase 1 regulatory subunit 12A 
isoform X13  
5.7E-04 0.316 
CCT5 12804225 Unknown (protein for IMAGE:3543711)  partial  5.9E-03 0.315 
ACP1 179661 cytoplasmic phosphotyrosyl protein phosphatase  
partial  
1.2E-03 0.315 
LMNB2 16306859 Lamin B2  1.2E-02 0.312 
SH3GLB2 9910352 endophilin-B2 isoform b  3.8E-03 0.309 
NFATC2IP 51873914 NFATC2IP protein  partial  1.1E-02 0.309 
CLPX 767983141 ATP-dependent Clp protease ATP-binding subunit 
clpX-like  mitochondrial isoform X1  
2.2E-03 0.309 
UBAP2L 568214245 ubiquitin-associated protein 2-like isoform c  3.5E-03 0.305 
PMPCA 194387808 unnamed protein product  5.8E-03 0.304 
SAFB 221045036 unnamed protein product  9.7E-03 0.304 
TMED1 5803040 transmembrane emp24 domain-containing protein 1 
precursor  
3.2E-03 0.302 
PDHB 119585776 pyruvate dehydrogenase (lipoamide) beta  isoform 
CRA_b  
1.1E-03 0.299 
PCCB 221044434 propionyl-CoA carboxylase 1.4E-03 0.293 
PTPRF 530363076 receptor-type tyrosine-protein phosphatase F 
isoform X9  
6.4E-03 0.291 
ENO1 4503571 alpha-enolase isoform 1  1.3E-02 0.291 
PPP1R8 20336239 nuclear inhibitor of protein phosphatase 1 isoform 
beta/delta  
2.1E-03 0.288 
CCDC43 119571973 coiled-coil domain containing 43  isoform CRA_a  3.9E-03 0.286 
MCM4 193785697 unnamed protein product  1.1E-05 0.286 
CCT3 194374631 unnamed protein product  6.2E-04 0.282 
PRPF3 194386352 unnamed protein product  1.3E-02 0.282 
XRCC5 62988844 unknown  6.4E-03 0.281 
ERP44 119579326 thioredoxin domain containing 4 (endoplasmic 
reticulum)  isoform CRA_a  partial  
6.2E-04 0.281 
SEPHS1 307219240 selenide  water dikinase 1 isoform 3  5.2E-03 0.278 
SRA1 9930614 steroid receptor RNA activator isoform 3  2.4E-03 0.276 
PPT1 194377188 unnamed protein product  2.4E-03 0.274 
PHPT1 12052814 hypothetical protein  1.0E-02 0.271 
BCL9L 530398008 B-cell CLL/lymphoma 9-like protein isoform X3  1.3E-02 0.271 
FKBP4 767971249 peptidyl-prolyl cis-trans isomerase FKBP4 isoform X1  1.5E-02 0.271 
DNMT1 4503351 DNA (cytosine-5)-methyltransferase 1 isoform b  9.3E-04 0.271 
PPP6C 183603931 serine/threonine-protein phosphatase 6 catalytic 
subunit isoform c  
8.7E-03 0.267 
SRRT 194382242 unnamed protein product  1.1E-02 0.266 
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SMAP1 194382546 unnamed protein product  1.4E-03 0.260 
LMNB1 5031877 lamin-B1 isoform 1  4.2E-03 0.260 
CFL2 14719392 cofilin-2 isoform 1  7.6E-04 0.259 
PBDC1 32306539 protein PBDC1 isoform 1  1.1E-02 0.259 
NUP107 530400597 nuclear pore complex protein Nup107 isoform X1  1.7E-03 0.258 
MRPL14 974005264 39S ribosomal protein L14  mitochondrial isoform d  1.1E-03 -0.312 
PAK2 984305 hPAK65  partial  3.0E-03 -0.313 
EWSR1 119580187 Ewing sarcoma breakpoint region 1  isoform CRA_d  2.2E-04 -0.314 
RAB11A 4758984 ras-related protein Rab-11A isoform 1  1.0E-03 -0.315 
EIF3J 3264861 eukaryotic translation initiation factor eIF3  p35 
subunit  
8.8E-03 -0.316 
TSTA3 4507709 GDP-L-fucose synthase  1.8E-03 -0.316 
XPNPEP1 34783912 XPNPEP1 protein  partial  8.3E-03 -0.318 
GRSF1 530376963 G-rich sequence factor 1 isoform X2  5.0E-03 -0.319 
HNRNPAB 55956921 heterogeneous nuclear ribonucleoprotein A/B 
isoform b  
8.8E-03 -0.319 
LMNA 119573385 lamin A/C  isoform CRA_d  3.1E-04 -0.321 
BLVRB 4502419 flavin reductase (NADPH)  4.1E-04 -0.322 
NAA50 817478488 N-alpha-acetyltransferase 50 isoform 2  1.4E-02 -0.322 
NDUFA5 47682777 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex  5  13kDa  
2.8E-03 -0.323 
IGBP1 4557663 immunoglobulin-binding protein 1  4.5E-03 -0.326 
FBP1 182311 fructose-1 6-bisphosphatase  1.3E-03 -0.327 
RPL35P5 119628326 hCG1983332  1.5E-02 -0.331 
NIPSNAP1 530420475 protein NipSnap homolog 1 isoform X1  2.8E-04 -0.332 
HSPA4L 119625602 heat shock 70kDa protein 4-like  isoform CRA_a  2.5E-03 -0.333 
LSM7 7706423 U6 snRNA-associated Sm-like protein LSm7  2.5E-04 -0.334 
DBNL 62198235 drebrin-like protein isoform b  1.2E-04 -0.335 
RPL21 18104948 60S ribosomal protein L21  1.3E-03 -0.337 
BCAR1 282398125 breast cancer anti-estrogen resistance protein 1 
isoform 8  
6.0E-06 -0.342 
NQO1 554790420 NAD(P)H dehydrogenase [quinone] 1 isoform d  3.4E-03 -0.343 
CTSD 4503143 cathepsin D preproprotein  6.7E-03 -0.344 
CHCHD2 7705851 coiled-coil-helix-coiled-coil-helix domain-containing 
protein 2 precursor isoform 2  
1.6E-04 -0.349 
SDF4 189054914 unnamed protein product  4.1E-04 -0.350 
CAMK2D 1010228622 calcium/calmodulin-dependent protein kinase type 
II subunit delta isoform 16  
1.8E-03 -0.356 
PSMF1 578835639 proteasome inhibitor PI31 subunit isoform X2  8.8E-04 -0.359 
TPM1 530406412 tropomyosin alpha-1 chain isoform X10  1.6E-03 -0.361 
ECHS1 194097323 enoyl-CoA hydratase  mitochondrial  7.4E-04 -0.362 
RPL6 21410970 Ribosomal protein L6  8.4E-04 -0.362 
VBP1 125987848 RecName: Full=Prefoldin subunit 3; AltName: 
Full=HIBBJ46; AltName: Full=Von Hippel-Lindau-
binding protein 1; Short=VBP-1; Short=VHL-binding 
protein 1 
4.7E-03 -0.363 
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NAP1L4 5174613 nucleosome assembly protein 1-like 4  1.3E-02 -0.365 
SSBP1 4507231 single-stranded DNA-binding protein  mitochondrial 
precursor  
4.5E-04 -0.366 
RANBP9 39645650 RANBP9 protein  1.4E-04 -0.367 
P4HB 20070125 protein disulfide-isomerase precursor  3.6E-06 -0.369 
SLC9A3R2 71897229 Na(+)/H(+) exchange regulatory cofactor NHE-RF2 
isoform b  
5.4E-05 -0.370 
MISP 27735067 mitotic interactor and substrate of PLK1  3.6E-03 -0.370 
CAPG 21730367 capping actin protein, gelsolin like - Chain A  Ca2+-
Binding Mimicry In The Crystal Structure Of The 
Eu3+-Bound Mutant Human Macrophage Capping 
Protein Cap G 
4.2E-04 -0.371 
MRPL46 26667177 39S ribosomal protein L46  mitochondrial  4.9E-04 -0.371 
HNRNPUL2 118601081 heterogeneous nuclear ribonucleoprotein U-like 
protein 2  
2.2E-03 -0.371 
DBN1 119605397 drebrin 1  isoform CRA_c  partial  5.8E-04 -0.372 
CHRAC1 8393116 chromatin accessibility complex protein 1  2.4E-06 -0.374 
ETFA 957949341 electron-transfer-flavoprotein alpha polypeptide 
isoform 3  partial  
2.6E-04 -0.374 
MRPL49 4826649 39S ribosomal protein L49  mitochondrial  2.5E-03 -0.375 
AK2 312836806 adenylate kinase 2  mitochondrial isoform c  7.1E-05 -0.376 
VIL1 189053947 unnamed protein product  1.0E-02 -0.376 
VDAC2 296317337 voltage-dependent anion-selective channel protein 
2 isoform 1  
2.8E-04 -0.377 
RELA 15079553 RELA protein  4.8E-04 -0.382 
PIN4 119592218 protein (peptidylprolyl cis/trans isomerase) NIMA-
interacting  4 (parvulin)  
2.8E-03 -0.383 
EPS8L2 21264616 epidermal growth factor receptor kinase substrate 
8-like protein 2  
2.5E-05 -0.383 
ZNF207 119600638 zinc finger protein 207  isoform CRA_b  2.9E-03 -0.384 
TST 62898774 thiosulfate sulfurtransferase variant  2.8E-03 -0.385 
AK1 4502011 adenylate kinase isoenzyme 1 isoform 1  2.5E-04 -0.386 
LRRFIP1 212276104 leucine-rich repeat flightless-interacting protein 1 
isoform 5  
1.5E-02 -0.388 
CORO1B 119595032 coronin  actin binding protein  1B  isoform CRA_c  5.8E-03 -0.397 
PFDN2 12408675 prefoldin subunit 2  9.3E-05 -0.399 
GSN 221045102 unnamed protein product  3.4E-03 -0.403 
PFDN6 7657162 prefoldin subunit 6  1.6E-03 -0.406 
FKBP9 33469985 peptidyl-prolyl cis-trans isomerase FKBP9 isoform 1 
precursor  
3.2E-03 -0.407 
PDRG1 38197489 PDRG1 protein  partial  5.7E-03 -0.407 
PEBP1 4505621 phosphatidylethanolamine-binding protein 1  1.5E-02 -0.408 
MTAP 386642469 methylthioadenosine phosphorylase  2.0E-04 -0.409 
PLIN4 194379754 unnamed protein product  3.9E-03 -0.412 
LDHA 62897717 lactate dehydrogenase A variant  3.6E-03 -0.414 
RPS17 4506693 40S ribosomal protein S17  1.2E-02 -0.417 
ETFB 119592410 electron-transfer-flavoprotein  beta polypeptide  1.2E-03 -0.418 
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EFHD2 20149675 EF-hand domain-containing protein D2  1.6E-02 -0.420 
AKR1B10 3150035 aldose reductase-like peptide  9.0E-03 -0.422 
PMVK 5729980 phosphomevalonate kinase  3.0E-03 -0.422 
TCEA3 767905824 transcription elongation factor A protein 3 isoform 
X5  
3.7E-03 -0.423 
RPL11 19851919 CLL-associated antigen KW-12  7.4E-03 -0.426 
TALDO1 48257056 TALDO1 protein  partial  1.2E-02 -0.438 
RPL12 4506597 60S ribosomal protein L12  2.2E-04 -0.444 
C9orf16 5002581 EST00098 protein  2.0E-05 -0.444 
NHS 38093637 Nance-Horan syndrome protein isoform 1  1.3E-02 -0.445 
RPS4X 48376549 RPS4X protein  partial  1.7E-03 -0.446 
LIMA1 62897503 epithelial protein lost in neoplasm beta variant  2.1E-04 -0.449 
CGN 119573820 cingulin  isoform CRA_b  9.5E-05 -0.449 
VASP 957950351 vasodilator-stimulated phosphoprotein isoform 3  
partial  
4.1E-03 -0.450 
KLK6 4506155 kallikrein-6 isoform A preproprotein  6.5E-03 -0.453 
EPS8 119616761 epidermal growth factor receptor pathway substrate 
8  isoform CRA_b  
7.5E-03 -0.455 
EML4 ALK 161176980 EML4/ALK fusion protein variant 3  6.4E-03 -0.455 
TPPP3 56676375 tubulin polymerization-promoting protein family 
member 3  
8.1E-03 -0.459 
PODXL 16550641 unnamed protein product  2.3E-03 -0.463 
RALB 194386002 unnamed protein product  4.0E-03 -0.464 
TATDN1 14042943 putative deoxyribonuclease TATDN1 isoform a  4.0E-03 -0.467 
CSRP1 193783759 unnamed protein product  1.4E-02 -0.467 
ACTN4 2804273 alpha actinin 4  7.1E-04 -0.482 
SNAP29 4759154 synaptosomal-associated protein 29  3.9E-04 -0.489 
RPL13 15431295 60S ribosomal protein L13 isoform 1  1.2E-02 -0.492 
RPS23 4506701 40S ribosomal protein S23  6.4E-04 -0.493 
GSTO1 300360532 glutathione S-transferase omega-1 isoform 2  5.8E-03 -0.498 
GRN 194382178 unnamed protein product  6.8E-04 -0.501 
BOLA2 46577124 RecName: Full=BolA-like protein 2 1.7E-03 -0.502 
MPST 432376 rhodanese  8.0E-03 -0.505 
RPS15 4506687 40S ribosomal protein S15 isoform 2  1.1E-03 -0.505 
PLEC 530389159 plectin isoform X13  4.8E-04 -0.508 
ARHGDIA 4757768 rho GDP-dissociation inhibitor 1 isoform a  7.7E-03 -0.510 
STAM 21040514 STAM protein  1.1E-03 -0.511 
ANP32A 578827458 acidic leucine-rich nuclear phosphoprotein 32 family 
member A isoform X1  
8.4E-03 -0.515 
SERPINB1 194388748 unnamed protein product  1.5E-03 -0.515 
ANXA4 1703319 RecName: Full=Annexin A4; AltName: Full=35-beta 
calcimedin; AltName: Full=Annexin IV; AltName: 
Full=Annexin-4; AltName: Full=Carbohydrate-binding 
protein p33/p41; AltName: Full=Chromobindin-4;  
1.2E-05 -0.520 
EXOSC4 9506689 exosome complex component RRP41  3.5E-03 -0.521 
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GSR 305410793 glutathione reductase  mitochondrial isoform 4 
precursor  
6.3E-04 -0.522 
COMT 6466450 catechol O-methyltransferase isoform S-COMT  4.5E-06 -0.528 
TXNDC5 30354488 TXNDC5 protein  2.8E-05 -0.529 
PYCR2 4960118 pyrroline 5-carboxylate reductase isoform  7.6E-06 -0.534 
KRT19 386803 40-kDa keratin protein  partial  8.6E-04 -0.543 
CMPK1 12644008 RecName: Full=UMP-CMP kinase; AltName: 
Full=Deoxycytidylate kinase; Short=CK; Short=dCMP 
kinase; AltName: Full=Nucleoside-diphosphate 
kinase; AltName: Full=Uridine 
monophosphate/cytidine monophosphate kinase;  
2.3E-03 -0.547 
TMOD3 6934244 tropomodulin 3  5.2E-05 -0.548 
TJP2 221044090 unnamed protein product  7.3E-04 -0.553 
PCBD1 348903 4a-carbinolamine dehydratase  partial  1.5E-02 -0.554 
YBX1 340419 Y box binding protein-1  1.4E-03 -0.555 
GMDS 3258631 GDP-D-mannose-4 6-dehydratase  1.9E-05 -0.559 
RPL19 62897725 ribosomal protein L19 variant  2.4E-04 -0.562 
PDAP1 7657441 28 kDa heat- and acid-stable phosphoprotein  6.4E-04 -0.563 
IRF2BP2 32306875 interferon regulatory factor-2 binding protein 2B  9.0E-06 -0.566 
RNASET2 5231228 ribonuclease T2 precursor  1.3E-03 -0.567 
POLR3K 597709807 DNA-directed RNA polymerase III subunit RPC10  1.5E-02 -0.571 
ARPC5 5031593 actin-related protein 2/3 complex subunit 5 isoform 
1  
1.3E-02 -0.572 
CALM2 4502549 calmodulin isoform 2  9.8E-03 -0.576 
SPTAN1 179106 nonerythroid alpha-spectrin  1.2E-05 -0.577 
PDIA3 860986 protein disulfide isomerase  6.2E-05 -0.589 
SFN 16306737 SFN protein  1.3E-03 -0.591 
SNCG 119600721 synuclein  gamma (breast cancer-specific protein 1)  
isoform CRA_a  
4.7E-05 -0.594 
MARCKS 187387 myristoylated alanine-rich C-kinase substrate  9.0E-04 -0.599 
RPL13A 111494155 RPL13A protein  6.3E-03 -0.600 
EHD1 194386692 unnamed protein product  5.3E-03 -0.601 
POF1B 530422196 protein POF1B isoform X2  4.2E-04 -0.602 
LYZ 157834713 Chain A  Contribution Of Hydrophobic Effect To The 
Conformational Stability Of Human Lysozyme 
1.0E-03 -0.604 
LGALS3BP 119609949 lectin  galactoside-binding  soluble  3 binding protein  
isoform CRA_a  
5.3E-06 -0.604 
TAGLN2 4507357 transgelin-2 isoform b  3.5E-03 -0.620 
EIF1AY 519666785 eukaryotic translation initiation factor 1A  Y-
chromosomal isoform 2  
1.7E-03 -0.621 
LGALS1 754496395 lectin  galactoside-binding  soluble  1  partial  4.4E-03 -0.634 
KRT80 31873640 hypothetical protein  1.2E-03 -0.634 
ITGA6 578804287 integrin alpha-6 isoform X2  6.2E-05 -0.635 
MVP 194389978 unnamed protein product  7.4E-04 -0.638 
FKBP10 119581172 FK506 binding protein 10  65 kDa  isoform CRA_b  7.7E-05 -0.646 
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CST3 364505964 Chain A  Crystal Structure Of L68v Mutant Of Human 
Cystatin C 
8.0E-03 -0.646 
TRMT2A 194384404 unnamed protein product  9.0E-04 -0.649 
C11orf54 37782472 LP4947  7.3E-05 -0.654 
TNKS1BP1 110556636 182 kDa tankyrase-1-binding protein  3.4E-05 -0.656 
DNPH1 673541350 Chain A  Crystal Structure Of Human Dnph1 (rcl) 
With 6-naphthyl-purine- Riboside-monophosphate 
4.0E-03 -0.656 
ANXA1 4502101 annexin A1  1.6E-05 -0.667 
LASP1 5453710 LIM and SH3 domain protein 1 isoform a  5.8E-04 -0.676 
PPA1 11056044 inorganic pyrophosphatase  8.9E-04 -0.679 
TOLLIP 6048243 TOLLIP protein  3.3E-04 -0.682 
TUBA4A 514052659 tubulin alpha-4A chain isoform 2  4.5E-04 -0.683 
CFL1 5031635 cofilin-1  7.8E-04 -0.696 
PDLIM5 221044868 Carboxyl Terminal LIM Domain Protein 5  7.3E-04 -0.698 
TSTD1 163965377 thiosulfate sulfurtransferase/rhodanese-like 
domain-containing protein 1 isoform 1  
2.6E-05 -0.714 
IDH2 588282794 isocitrate dehydrogenase [NADP]  mitochondrial 
isoform 3  
7.5E-06 -0.716 
CSPG4 34148711 melanoma chondroitin sulfate proteoglycan  8.8E-03 -0.723 
SCP2 302344767 non-specific lipid-transfer protein isoform 8  1.1E-06 -0.751 
MUC5AC 748983076 mucin-5AC precursor  5.1E-03 -0.771 
NAPRT 33991172 NAPRT1 protein  6.7E-04 -0.777 
RRBP1 23822112 RecName: Full=Ribosome-binding protein 1; 
AltName: Full=180 kDa ribosome receptor homolog; 
Short=RRp; AltName: Full=ES/130-related protein; 
AltName: Full=Ribosome receptor protein 
1.3E-03 -0.795 
GPD2 193787465 unnamed protein product  1.0E-03 -0.830 
AGR2 5453541 anterior gradient protein 2 homolog precursor  2.4E-03 -0.830 
TESC 767974680 calcineurin B homologous protein 3 isoform X1  1.8E-04 -0.834 
SPEF2 767934681 sperm flagellar protein 2 isoform X4  2.6E-03 -0.835 
ARVCF 119623413 armadillo repeat gene deletes in velocardiofacial 
syndrome  isoform CRA_b  
1.8E-04 -0.839 
SERPINB5 453369 maspin  1.3E-04 -0.878 
AKR1C3 1815604 3-alpha-hydroxysteroid dehydrogenase  3.1E-03 -0.882 
C1orf116 12653943 Chromosome 1 open reading frame 116  5.4E-05 -0.882 
ACAA2 189069404 unnamed protein product  5.2E-04 -0.903 
UGDH 151567925 Chain A  Structure Of Human Udp-glucose 
Dehydrogenase Complexed With Nadh And Udp-
glucose 
2.5E-04 -0.905 
EPS8L1 33341720 PP10566  3.2E-04 -0.916 
G6PD 452269 glucose-6-phosphate dehydrogenase  3.1E-04 -0.924 
CKB 119602226 creatine kinase  brain  isoform CRA_a  4.0E-04 -0.941 
LAD1 119611770 ladinin 1  isoform CRA_b  1.1E-03 -0.970 
SH3BGRL3 13775198 SH3 domain-binding glutamic acid-rich-like protein 3  8.0E-05 -0.979 
MIF 4505185 macrophage migration inhibitory factor  5.2E-03 -0.980 
RANBP1 119623391 RAN binding protein 1  isoform CRA_a  1.3E-06 -0.981 
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CRIP2 62898063 cysteine-rich protein 2 variant  1.2E-06 -0.994 
SERPINA1 6855601 PRO0684  1.1E-04 -1.010 
EPPK1 119602582 epiplakin 1  2.7E-03 -1.011 
STARD10 119595276 START domain containing 10  isoform CRA_c  1.2E-04 -1.054 
CAPG 1002819390 macrophage-capping protein isoform 3  9.9E-05 -1.086 
HSPA1A 194388088 unnamed protein product  2.9E-04 -1.253 
BCAS1 530418484 breast carcinoma-amplified sequence 1 isoform X6  3.5E-04 -1.283 
PFN2 16753215 profilin-2 isoform a  4.1E-07 -1.347 
KRT20 27894337 keratin  type I cytoskeletal 20  5.9E-03 -1.406 
KRT18 30311 cytokeratin 18 (424 AA)  1.1E-03 -1.408 
LYVE1 40549451 unnamed protein product  1.3E-04 -1.416 
CRIP1 4503047 cysteine-rich protein 1  4.0E-04 -1.635 
MSN 4505257 moesin  1.1E-04 -1.763 
H2A 15826398 Chain A  Crystal Structure Of The Nc2-Tbp-Dna 
Ternary Complex 
2.2E-03 -1.785 
CA2 245850 S-100P=Ca(2+)-binding protein  1.9E-04 -1.813 
 
 
